INTRACELLULAR DELIVERY

专利摘要:
intracellular delivery. the present invention relates to a microfluidic system to cause disturbances in a cell membrane, in which the system includes a microfluidic channel that defines a lumen and is configured so that a cell suspended in a buffer can cross it, in that the microfluidic channel includes a cell-deforming constriction, where a diameter of the constriction is a function of the cell diameter.
公开号:BR112014009346B1
申请号:R112014009346-6
申请日:2012-10-17
公开日:2020-09-15
发明作者:Armon Sharei；Andrea Adamo；Robert Langer；Klavs F. Jensen
申请人:Massachusetts Institute Of Technology；
IPC主号:

专利说明:

RELATED DEPOSIT REQUESTS
[001] This application claims priority over US Provisional Patent Application No. 61 / 548,013, filed on October 17, 2011 and US Provisional Patent Application No. 61 / 684,301, filed on August 17, 2012, contents of each are hereby incorporated by reference. DECLARATION REGARDING FEDERALLY SPONSORED RESEARCH
[002] This invention was made, at least in part, with the support of the Government through Concession 5 RC1 EB011187-02, granted by the National Institute of Health (National Institute of Health). The Government has certain rights in this invention. BACKGROUND
[003] Many drugs largely focus on the development of small molecule drugs.
[004] These drugs are so called due to their relatively small size, which enables them to spread freely throughout the body to reach their target. These molecules are also able to slide across the normally impermeable cell membrane, which is largely unimpeded. The next generation of therapies based on protein, DNA or RNA, however, cannot readily cross the cell membrane and therefore require cell modification to facilitate delivery.
[005] The established methods use chemicals or electrical pulses to break the membrane and deliver the material inside the cytoplasm. Proper intracellular delivery is a critical step in the research, development and implementation of the next generation of therapies.
[006] Existing methods are often difficult to develop and highly specific to your particular application. In addition, many clinically important cell types, such as stem cells and immune cells, are not properly addressed by existing methods. There is, therefore, a need for a more robust and precise technique capable of addressing the needs of modern biological / medical research. SUMMARY
[007] The invention is based on the surprising finding that a controlled lesion, for example, which subjects a cell to constriction, rapid stretching, rapid compression or high shear rate pulse, leads to the retention of molecules within the cytoplasm of the cell from the surrounding cell medium. Thus, the invention features a vector-free microfluidic platform for direct intracellular delivery to the cytosol of materials, for example, a compound or a composition, to a eukaryotic cell. The device is useful as a versatile and widely applicable laboratory tool for delivering the desired molecules within the target cells. The delivery of molecules to the cell using the methods described in this document is proportional, for example, linearly or monotonically to the cell velocity through constriction and / or pressure. For example, 50 μl of cell suspension passes through the device in a few seconds. The flow rate ranges from 1 cell / second per channel (or even less) to over 1,000 cells / second per channel. Typical cell speeds through constriction include 10 mm / second to 500 mm / second, although cell speeds can be up to 10 m / s (or even higher). Additional channels can be placed in parallel to increase the total flow of the system.
[008] The reception of the molecule is based on diffusion instead of endocytosis, that is, the payload (compound (s) to be delivered to the cell) is presented in the cytoplasm instead of endorsing that follow the passage through the device. Little or no payload appears in the endosomes that follow cell treatment. For example, large molecules are taken more slowly than smaller molecules. Controlled cell stretching and the speed of cell movement through constriction leads to superior delivery of target molecules while preserving cell viability and integrity. After treatment, cell viability is between 70 to 100%, for example, typical viability is 90% after treatment. By comparison, previous delivery methods that use high shear rates for just seconds or milliseconds have been shown to lead to poor cell viability after treatment. In contrast, in the prior art, the methods of the invention subject cells to a shear pulse that varies from 100 to 1000 Pa for a very short period of time (approximately 100 microseconds) as the cell passes through constriction. The present techniques, however, are fundamentally different from the previous techniques. In the present techniques, there is preferably a total mechanical deformation of the cell as it passes through constriction, which can impose different shear forces than the previous techniques. In preferential modalities, the cells are not subjected to an electric current. In other embodiments, a combination treatment is used, for example, the mechanical deformation of the device described in this document is used followed by or preceded by electroporation (a type of osmotic transfection in which an electric current is used to produce temporary orifices) in cell membranes, which allows the entry of nucleic acids or macromolecules).
[009] A payload is a compound or composition to be delivered to a cell. For example, a payload can include proteins, fluorescent dyes, quantum dots, carbon nanotubes, RNA molecules, DNA molecules, antigens and other macro-molecules, nanoparticles and compositions of matter.
[0010] The width of the device's constriction, the length of the constricted portion, the geometry of the entry region and the depth of the device's channel influence the delivery of the molecules inside the cell. Preferably, the width of the constricted portion of the conduit is no more than 4 pm in diameter and the length of the constricted portion of the conduit is preferably between 40 to 50 pm. The length of the constricted portion generally does not exceed 90 pm. The diameter of the constricted portion is related to the type of cell to be treated. As described below, the diameter is less than the cell diameter (for example, 20 to 99% of the cell diameter). Many cells are between 5 to 15 pm in diameter, for example, dendritic cells are 7 to 8 pm in diameter. For example, the diameter of the constriction portion is 4.5, 5, 5.5, 6 or 6.5 pm for processing cells alone. In another example, the size / diameter of the constricted portion for processing a human egg is between 6.2 pm and 8.4 pm, although larger and smaller constrictions are possible (the diameter of a human egg is approximately 12 pm). In yet another example, embryos (for example, clusters of 2 to 3 cells) are processed using a constriction diameter of between 12 pm and 17 pm.
[0011] The device and methods are useful in vaccine development and in production using cells that have experienced antigens such as, for example, dendritic cells. For example, a method of presenting a stimulating antigen is performed by submitting a dendritic cell to a controlled lesion, for example, transient constriction or high-shear pulse, which comes into contact with the dendritic cell with a solution comprising a target antigen. The method yields cells that have highly activated antigens compared to previous stimulation methods. Vaccine production is performed by propelling dendritic cells or other cells that have antigen through the device that contains constriction (thereby subjecting the cells to a rapid stretching event) and then incubating the cells in a solution containing the payload, for example, antigen. The cells are bathed in a cell culture medium containing one or more antigens after the rapid deformation of the cells, but the cells can be brought into contact with the antigen prior to, during and / or after the rapid deformation event / process .
[0012] Surfactants (for example, 0.1 to 10% w / w) are optionally used (for example, poloxamer, animal-derived serum, albumin protein) in the flow buffer. The delivery of molecules inside cells is not affected by the presence of surfactants; however, surfactants are optionally used to reduce clogging of the device during operation.
[0013] The device is made from silicon, metal (for example, stainless steel), plastic (for example, polystyrene), ceramics or any other material suitable for carved micron scale features and includes one or more channels or conduits through which cells pass through. Silicon is particularly well suited, due to the fact that methods and micro standardization are well established with this material, so it is easier to manufacture new devices, change designs, etc. In addition, silicon stiffness can provide advantages over more flexible substrates such as polydimethylsiloxane (PDMS), for example, higher delivery rates. For example, the device includes 2, 10, 20, 25, 45, 50 75, 100 or more channels. The device is microfabricated by carving silicon. The cells are moved, for example, pushed, through channels or conduits by applying pressure. A cell actuator can apply pressure. A cell actuator can include, for example, a pressure pump, a gas cylinder, a compressor, a vacuum pump, a syringe, a syringe pump, a peristaltic pump, a manual syringe, a pipette, a piston, a capillary and gravity actuator. As an alternative to the channels, the cells can be passed through a constriction in the form of a network or closely arranged plates. In either case, the width of the constriction through which the cells traverse is 20 to 99% of the width or diameter of the cell to be treated in its natural, that is, stress-free state. Temperature can affect the reception of the compositions and affects viability. The methods are performed at room temperature (for example, 20'0), physiological temperature (for example, 390), higher than the physiological temperature or reduced temperature (for example, 40) or the temperatures between these and examples.
[0014] After controlled cell injury through constriction, stretching and / or a high shear rate pulse, cells are incubated in a delivery solution containing the compound or molecule that an individual wishes to introduce into the cell . The controlled lesion can be characterized as a small, for example, 200 nm in diameter, defect in the cell membrane. The recovery period for the cells is in the order of a few minutes next to the injury caused by the passage of the through the constriction. The delivery period comprises 1 to 10 minutes or longer, for example, 15, 20, 30, 60 minutes or more, with 2 to 5 minutes being ideal when operated at room temperature. Longer periods of incubation in the delivery solution do not necessarily yield increased retention. For example, the data indicates that after 5 minutes, little or no additional material is taken up by the cells.
[0015] In this way, the invention provides a solution to established problems in the field of drug delivery to cells and to inconveniences associated with the earliest methods.
[0016] Regarding the delivery of material to a eukaryotic cell, cells can be classified into two main categories:
[0017] 1) Easy to deliver cells (ETD): Most of the chemical and viral methods available fall into this category. Easy-to-deliver cells often have no direct clinical relevance.
[0018] 2) Difficult to deliver cells (DTD): High clinical relevance. Advances in delivery technology can largely enable / accelerate the development of innovative therapies. This category includes stem cells, primary cells and immune cells. The market for DTD delivery is expected to grow dramatically as the innovative RNA, stem cell and therapeutic-based protein gain momentum in the years to come.
[0019] The techniques described in this document have proven to be especially useful for the areas of DTD research, although the same techniques can be used with ETD cells. In addition, it has facilitated the delivery of materials (such as quantum dots, carbon nanotubes and antibodies) that cannot be delivered E-fetively by any other method for both ETD and DTD cells.
[0020] In general, in one aspect, the implantations of the invention can provide a microfluidic system to cause disturbances in a cell membrane, wherein the system includes a microfluidic channel that defines a lumen and is configured so that a cell suspended in a buffer can pass through it, where the microfluidic channel includes a constriction, where a diameter of the constriction is a function of the diameter of the cell.
[0021] The deployments of the invention may also provide one or more of the following features. The diameter of the constriction is substantially 20 to 99% of the diameter of the cell that passes through it. A channel cross section is selected from the group consisting of a circular, elliptical, elongated, square, hexagonal and triangular slit. The constriction includes an entry portion, a center point and an exit portion. The inlet portion defines a constriction angle, in which the constriction angle is optimized to reduce channel obstruction. The microfluidic system further includes a plurality of microfluidic channels arranged in parallel, for example, 2, 5, 10, 20, 40, 45, 50, 75, 100, 500, 1,000 or more.
[0022] In general, in another aspect, the implantations of the invention may also provide a method for delivering a compound in a cell, wherein the method includes providing a cell in suspension or suspending a cell and a payload in a solution, which passes the solution through a microfluidic channel that includes a constriction, which sizes the constriction as a function of the cell diameter, which passes the cell through the constriction so that a pressure is applied to the cell that causes cell disturbances large enough for the payload to pass through and that incubates the cell in the solution for a predetermined period of time after it has been constricted.
[0023] The deployments of the invention may also provide one or more of the following resources. A diameter of the constriction is substantially 20 to 99% of the cell diameter. A cross section of the microfluidic channel is selected from the group consisting of a circular, elliptical, elongated, square, hexagonal and triangular slit. Passing the solution includes passing the solution through an inlet portion, a central point and an outlet portion of the constriction. The method further includes reducing the obstruction of the microfluidic channel by adjusting the constriction angle of the inlet portion. The solution includes passing the solution through a plurality of microfluidic channels arranged in parallel.
[0024] In general, in yet another aspect, the implantations of the invention may also provide a method for delivering a compound to a cell, wherein the method includes providing a cell in a solution or suspending a cell in a solution, which passes the solution through a microfluidic channel that includes a constriction, which sizes the constriction as a function of the cell's diameter, which passes the cell through the constriction so that a pressure is applied to the cell which causes cell disturbances and which incubates the cell in the solution containing a payload for a predetermined period of time after it goes through a constriction, in which the disturbances are large enough for the payload to pass through.
[0025] The deployments of the invention may also provide one or more of the following features. A diameter of the constriction is substantially 20 to 99% of the cell diameter. A cross section of the microfluidic channel is selected from the group consisting of a circular, elliptical, elongated, square, hexagonal and triangular slit. Passing the solution includes passing the solution through an inlet portion, a central point and an outlet portion of the constriction. The method further includes reducing the obstruction of the microfluidic channel by adjusting the constriction angle of the inlet portion. Passing the solution includes passing the solution through a plurality of microfluidic channels arranged either in series or in parallel. Incubation includes incubating the cell for 0.0001 seconds to 20 minutes (or even longer). The pressure is one of shear and compression.
[0026] In general, in yet another aspect, the implantations of the invention may also provide a method for delivering a compound to a cell, wherein the method includes providing a cell in a solution or suspending a cell in a solution, which deforms the cell so that disturbances are caused in a cell membrane and which incubates the cell in solution with a payload after a cell has been deformed.
[0027] The deployments of the invention may also provide one or more of the following features. The cell definition includes deforming the cell by 1 ps to 10 ms, for example, 10 ps, 50 ps, 100 ps, 500 ps and 750 ps. The incubation takes place for 0.0001 seconds to 20 minutes, for example, 1 second, 30 seconds, 90 seconds, 270 seconds and 900 seconds.
[0028] The various deployments of the invention can provide one or more of the following capabilities. Greater accuracy and scalability of delivery can be achieved when compared to previous techniques. The delivery of a material to a cell can be automated. Material such as proteins, RNA, siRNA, peptides, DNA and impermeable dye can be implanted in a cell, such as embryonic stem cells or induced pluripotent stem cells (iPSCs), primary cells or strains of immortalized cells. The device and methods are sensitive to any type of cell and the size of the constricted portion is tailored to the cell to be treated. Devices and methods can provide significant advantages. For example, experimental noise in current systems can be reduced when compared to previous techniques.
[0029] Delivery quantities for a material can be consistent across the cell population. The cells can be handled individually instead of being handled as a batch. The invention has also demonstrated a reasonably unique opportunity to deliver a variety of nanoparticles and proteins to the cytosol. Existing methods are reasonably unreliable or inefficient in performing such functions.
[0030] Regarding the delivery of sensitive payloads, for example, proteins (specifically large proteins, for example, greater than 30, 50, 100, 150, 200, 300, 400, 500 kDa or more), points quantum or other payloads that are sensitive to or damaged by exposure to electricity, are reliably delivered inside cells while preserving the integrity and activity of the sensitive payload. Thus, the device and methods have significant advantages through existing techniques, such as electroporation, with payload compositions subjected to electricity (thereby damaging the payload) and brought to low cell viability ( for example, 505 or more of the cells typically die after electroporation).
[0031] Another advantage of the method of rapid stretching / deformation is that the stem cells or precursors become receptive to retain the payload without changing the state of differentiation or activity of the treated cell. In addition to delivering the compositions within the cell cytoplasm for therapeutic purposes, for example, vaccine production, the method is used to introduce molecules, for example, large molecules that comprise a detectable label, to label intracellular structures such as, for example, organelles or to identify intracellular constituents for diagnostic or imaging purposes.
[0032] The various deployments of the invention may also provide one or more of the following capabilities. DNA can be delivered within dose cells for delivery, such as stem cells, primary and immunological. Delivery of very large plasmids (even whole chromosomes) can be accomplished. Quantitative delivery within cells of known quantity of a gene construct to study the level of expression of a gene of interest and its sensitivity to concentration can also be readily accomplished. The delivery of known amounts of DNA sequences together with known amount of enzymes that enhance DNA recombination in order to obtain easier / more efficient stable delivery, homologous recombination and specific site mutagenesis can be accomplished. The methods and devices described in this document may also be useful for quantitative RNA delivery for more efficient / conclusive RNA studies.
[0033] The delivery of small interfering RNA (siRNA) within the cytoplasm of a cell is also readily accomplished.
[0034] The various deployments of the invention may also provide one or more of the following capabilities. RNA can be delivered to a cell for RNA silencing without the need for liposomes. The known amounts of RNA molecules together with the known amounts of dicer molecules can be delivered to achieve standardized and effective RNA across multiple cell lines under different conditions. The mRNA can be delivered inside cells to study aspects of gene expression regulations at the post-transcriptional level. Known amounts of RNA label to study the half-life of RNAs and cells may be possible. Universal protein delivery can be achieved. Known amounts of label proteins can be delivered to study their cell half-life. The delivery of label proteins to study the protein site can be accomplished. The known amounts of tagged proteins can be delivered to study protein-protein interactions in the cell environment. Delivery of labeled antibodies within living cells for immunostaining and fluorescence-based Western blotting can be achieved.
[0035] The various implantations of the invention can also be provided with one or more of the following clinical and research capabilities. Quantitative drug delivery to cell models for improved screening and dosage studies can be achieved. The method can be used as a high flow rate method of screening protein activity in the cytosol to help identify protein therapies or understand the desired mechanisms. Such applications are severely limited by current protein delivery methods due to their inefficiencies. The devices and techniques are useful for the intracellular delivery of drugs to a specific subset of circulating blood cells (for example, lymphocytes), the delivery of high flow of sugars inside the cells to improve the cryopreservation of the cells, specifically oocysts, targeted cell differentiation through the introduction of proteins, mRNA, DNA and / or growth factors, delivery of genetic material or protein to induce cell reprogramming to produce iPS cells, delivery of DNA and / or recombination enzymes within embryonic stem cells for the development of transgenic stem cell lines, delivery of DNA and / or recombination enzymes within zygotes for the development of transgenic organisms, DC cell activation, generation of iPSC and the differentiation of stem cells, the delivery of nasoparticles for diagnostics and / or mechanical studies as well as the introduction of quantum dots. Hair cells used in conjunction with plastic surgery are also modified using the devices and method described in this document.
[0036] An antigen-stimulating presentation method that uses the method to deliver antigen and / or immunostimulatory molecules yield cells that have antigen, for example, dendritic cells, with improved levels of activity compared to conventional methods of stimulation, thereby leading to increased levels of immunity mediated by B and T cells to a target antigen. Such a method can therefore be used as a means of activating the immune system in response to cancer or infections.
[0037] For screening, imaging or diagnostic purposes, the device is used in a cell labeling method. A method of labeling a cell is performed by subjecting a cell to a controlled lesion that comes into contact with the cell with a solution comprising a detectable marker, wherein said lesion comprises a transient constriction or high-shear pulse. The detectable marker comprises a fluorescent molecule, a radionuclide, quantum dots, gold nanoparticles or magnetic microspheres.
[0038] Prior to the invention, manipulation of stem cells for the purpose of introducing exogenous compositions has been difficult. The device and methods described in this document, for example, the passage of stem cells or progenitor cells such as induced pluripotent stem cells (iPSCs) through a constriction channel does not induce differentiation, but reliably induces retention of the compositions inside the cell. For example, differentiating factors are introduced into such cells. After retaining the introduced factors, cells proceed on a differentiation path dictated by the factor introduced without complications associated with the method by which the factor (s) was introduced into the cell.
[0039] In addition to the only cells, even very large cells, for example, eggs; approximately 200 pm in diameter, cell clusters, for example 2 to 5 cell clusters, such as an embryo comprising 2 to 3 cells, are treated to make target compositions. The size of the opening is adjusted accordingly, that is, so that the width of the constriction is just below the size of the cluster. For example, the width of the channel is 20 to 99% of the width of the grouping cell.
[0040] The cells or cell clusters are purified / isolated or enriched for the desired cell type. Dendritic cells or other cells, for example, immune cells, such as macrophages, B cells, T cells, or stem cells, such as embryonic stem cells or iPS, used in the methods are purified or enriched. For example, cells are isolated or enriched because of their expression of cell surface markers or other identifying characteristics. Dendritic cells are identified and isolated by virtue of their expression of â-integrin, ICD lc or other identification cell surface markers. With respect to cells, the term "isolated" means that the cell is substantially free of other types of cell or cellular material with which it naturally occurs.
[0041] For example, a sample of cells of a specific type or phenotype of tissue is "substantially pure" when it is at least 60% of the cell population. Preferably, the preparation is at least 75%, more preferably at least 90% and most preferably at least 99% or 100%, of the cell population. Purity is measured by any appropriate standard method, for example, by fluorescence activated cell classification (FACS).
[0042] Payload compositions such as polynucleotides, polypeptides or other agents are purified and / or isolated. Specifically, as used herein, an "isolated" or "purified" nucleic acid molecule, polynucleotide, polypeptide or protein, is substantially free of other cellular material or culture medium when produced by recombinant techniques or chemical precursors or other chemicals when chemically synthesized. The purified compounds are at least 60%, by weight (dry weight) of the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90% and most preferably at least 99%, by weight of the compound of interest. For example, a purified compound is one that is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99% or 100% (w / w) of the desired compound by weight. Purity is measured using an appropriate standard method, for example, through column chromatography, thin layer chromatography or high performance liquid chromatography (HPLC) analysis. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free from the genes or sequences that flank it in its naturally occurring state. Examples of an isolated or purified nucleic acid molecule include: (a) DNA that is part of a naturally occurring genomic DNA molecule, but is not flanked by both of the nucleic acid sequences that flank that part of the molecule in the genome the organism in which this occurs naturally; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in such a way that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule, such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR) or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, that is, a gene that encodes a fusion protein. The isolated nu-nucleic acid molecules according to the present invention further include synthetically produced molecules, as well as any nucleic acids that have been chemically altered and / or have modified backbones.
[0043] A suspension solution is any buffer or physiological or cell-compatible solution. For example, a suspension solution is the cell culture medium or phosphate buffered saline. A payload is the same or a different suspension solution, which also contains the composition intended to be delivered inside the cell.
[0044] The advantages of the device include avoiding the modification of the desired payload and does not necessarily expose the payload to any electromagnetic fields or other forms of stress. Regarding electroporation, this method has been shown to damage proteins and to be inefficient in delivery. The significant drawback is not a problem with the method described in this document; the present method is particularly suitable for delivering sensitive payloads, for example proteins, particularly large proteins (for example, 40 kDa -70 kDa and up to 120, 130, 150, 200 kDa or more), large nucleic acid constructs ( for example, plasmids and other constructs that contain 1 kb, 2 kb, 5 kb or more of nucleic acid polymers and even whole chromosomes), large compounds, as well as quantum dots (for example, 12 nm in diameter) and other materials that they are known to be sensitive and easily damaged by exposure to electricity. For example, surface binders in a nanoparticle or quantum dot can be damaged or become charged in response to an electric field, thereby resulting in the aggregation of particles, thereby limiting / eliminating their functionality. Yet another advantage of the controlled injury method is the timing of contact between the cells and the release composition. Particularly relevant to proteins, which are sensitive to protease, temperature, as well as electricity, cells are brought into contact with the payload solution after treatment and for a relatively short period of time compared to earlier methods. The microfluidic nature of the device also requires much smaller workloads, thereby conserving precious raw materials and / or cells. The device can also be coupled with existing delivery methods, such as electroporation or liposomes, to produce a widely accentuated delivery in relation to each individual method.
[0045] The activity of the delivered payload is inversely correlated with fluid shear stress, that is, the physical stress on the cell membrane, such as stretching the cell membrane upon receiving the payload instead of shear. Conventional nanoparticle delivery methods can result in larger amounts of material gaining access to the cell's intracellular environment; however, these methods lead to less activity of the material delivered compared to the methods described in this document due to the fact that the previous methods result in sequestration of the material delivered in the endorsements. The methods described in this document lead to direct delivery of compounds / compositions to the cytosol so that a lower amount of payload delivered inside the cell leads to a greater amount of functional activity of the delivered molecules due to their accessibility to other cytosolic components. For example, previous methods for delivering nanoparticles have resulted in 2 to 10 times the amount of material delivered inside the cell, but with little or no functional activity from the material delivered due to kidnapping we endorse. The devices and methods of the invention have overcome this drawback of previous intracellular delivery methods by avoiding the endosomal compartment.
[0046] The advantages and additional features include time-scale treatment and cell speeds that are much faster than previous approaches. In addition, the other methods do not squeeze the cells as hard as the present methods, for example, as determined by the size (diameter) of the cell in relation to the size (diameter) of the constriction (as a% of the diameter of the cell). This fast, forced compression or deformation, but below the level of the leather, leads to superior results in the retention of direct payload for cytosol by the cells. The deformation of the cell is sudden, that is, it occurs through substantially 1is to 1ms. In general, excess strain-inducing cell stress can be lethal to the cell, while at the same time, very little stress does not induce cell disorders.
[0047] Therefore, the current article provides methods and systems that cause enough stress to induce temporary disturbances, but not so much stress that the disturbances are permanent and lethal to the cell.
[0048] Any of the methods described above is performed in vitro, ex vivo or in vivo. For in vivo applications, the device can be implanted in a vascular lumen, for example, an in-line stent. These and other capabilities of the invention, together with the invention itself, will be better understood to the full after an analysis of the following Figures, the detailed description and the claims. BRIEF DESCRIPTION OF THE FIGURES
[0049] FIG. 1a is a schematic diagram of a microfluidic system. The cells are exposed to the delivery material (payload) after passing through the constriction.
[0050] FIG. 1b is a schematic diagram of a microfluidic system. The cells are exposed to the application of material (payload) throughout the process by suspending the cells in a solution that includes the delivery material (payload) (for example, the cells are exposed to the delivery material before and after pass through the constriction).
[0051] FIG. 2A is a schematic diagram of an embodiment of a microfluidic system.
[0052] FIG. 2B is an illustrative diagram of a microfluidic system that depicts depth, width and length.
[0053] FIG. 3 is a schematic diagram of a microfluidic system.
[0054] FIG. 4 is a schematic diagram showing disturbances in a cell wall.
[0055] FIG. 5 is a photograph of a microfluidic system.
[0056] FIG. 6 is a photograph of a microfluidic system.
[0057] FIG. 7 is a photograph of a microfluidic system.
[0058] FIGS. 8a to 8b are graphs showing exemplary results obtained from a microfluidic system.
[0059] FIG. 9 is a graph showing the exemplary results obtained from cells that have been processed using a microfluidic system.
[0060] FIG. 10 is a graph showing the exemplary results obtained from cells that were processed using a microfluidic system.
[0061] FIG. 11 is a graph that shows the exemplary results obtained from cells that were processed using a microfluidic system.
[0062] FIG. 12 is a schematic diagram of a microfluidic system.
[0063] FIG. 13 is a graph showing the exemplary results obtained from cells that were processed using a microfluidic system.
[0064] FIG. 14 is a graph showing the exemplary results obtained from cells that were processed using a microfluidic system.
[0065] FIG. 15 is a graph that shows the exemplary results obtained from cells that were processed using a microfluidic system.
[0066] FIGS. 16a to 16f are exemplary schematic diagrams of the microfluidic system.
[0067] FIG. 17 is a flow chart related to a method of using a microfluidic system.
[0068] FIGS. 18a to 18b are graphs showing the exemplary results obtained from cells that were processed using a microfluidic system.
[0069] FIG. 19 is an overlay of the delivery and confocal fluorescence images, followed by confocal fluorescence images of section z of the treated cells delivered with quantum dots (QDs) using the current material.
[0070] FIG. 20A illustrates the efficiency of application inside the HeLa cell cytosol by treating the current material with QDs coated with polyimidazole ligand (PIL). Cell viability was> 80% as measured by flow cytometry.
[0071] FIG. 20B illustrates the viability of HeLa cells by delivering pure QD535 to the current matter, as measured by propidium iodide staining and flow cytometry measurement.
[0072] FIG. 21 illustrates the design of the construct, absorbance and stability in various media.
[0073] FIG. 22A illustrates live cell confocal microscopy images of treated and control cells.
[0074] FIG. 22B illustrates a change in the intensity of the treated cells as a function of time in the green and red channels.
[0075] FIG. 23 illustrates flow cytometry measurements of fluorescence and medium cell viability.
[0076] FIG. 24 illustrates fluorescence imaging of single non-aggregated quantum dots within the cell cytosol after treatment of the device with a 10 nM quantum dot solution and intermittent traces of the three quantum dots with autofluorescence.
[0077] FIG. 25 illustrates the experimental results that show that the delivery performance depends on the cell speed and the constriction design.
[0078] FIG. 26 illustrates scans of different horizontal planes of a HeLa cell after delivery of conjugated 3kDa pacific blue dextran, as measured by confocal microscopy.
[0079] FIG. 27 illustrates a simplified 2D diffusion model that simulates the passive diffusion of the material in a cell through a porous membrane.
[0080] FIG. 28 illustrates the results of a delivery in two rows of the material.
[0081] FIG. 29 illustrates data related to SiRNA, protein and nanoparticle delivery. FIG. 30 illustrates the applicability of current matter across cell types. FIG. 31 illustrates data on nanomaterial and antibody delivery.
[0082] FIG. 32 illustrates the applications of protein delivery.
[0083] FIG. 33 is a table of exemplary cell types, which has successfully delivered the payload.
[0084] FIG. 34 is an illustration depicting a system in which a patient's blood is treated using a microfluidic device for the application of payload, such as macromolecules.
[0085] FIG. 35 illustrates the delivery efficiency and viability of human embryonic stem cells treated with a 10im to 6im device to deliver the payload.
[0086] FIG. 36 depicts the generation and characterization of the mouse and human iPSC line by direct delivery of the reprogramming proteins fused using current material.
[0087] FIG. 37 depicts the preliminary protein programming results and depicts the expression of the human embryonic stem cell marker Oct4, SSEA-4, Tra-60, Tra-80, Alkaline Phosphatase (AP) in iPSC colonies.
[0088] FIG. 38 depicts the micrographs that illustrate a device modified by the electrodes incorporated on either side of the constriction by the photo lithographic pattern and the Au deposition introduces an electric field located inside the channel, thus combining cell deformation with electroporation .
[0089] FIG. 39 depicts another embodiment of the microfluidic system in which the inlet portion has a 90 degree constriction angle.
[0090] FIG. 40A and 40B are diagrams showing a comparison of viability and delivery efficiency between a device according to an example embodiment shown in FIG. 2A and a device according to an example embodiment shown in FIG. 39.
[0091] FIG. 41 is a histogram of CD45 expression of activated T cells as measured by an Alexa 488 antibody to CD45. Cells that are treated by the device in the presence of CD45 silencing RNA exhibit a lower peak of fluorescence intensity, thereby indicating the overthrow of CD45 gene expression.
[0092] FIG. 42 is an illustration depicting various fields of application example, for example, regenerative medicine; immunology; imaging and sensing; and cancer vaccines and cancer research.
[0093] FIG. 43A and 43B are histograms of flow cytometry intensity of a control population that is exposed to conjugated 3kD dextron cascade blue and a cell population that was subjected to a 30im to 6im device and then exposed to 3kDa dextran.
[0094] FIG. 44 is a bar graph that illustrates the knockout of GFP in human embryonic stem cells after treatment with the use of the microfluidic device and related methods. DETAILED DESCRIPTION
[0095] Modalities of the invention provide techniques for applying controlled deformation to a cell for a predetermined amount of time in order to cause disturbances in the cell membrane so that materials can be transmitted into the cell. Deformation can be caused by, for example, pressure induced by mechanical stress or shear forces. In one example, a microfluidic system includes a structure that controls and / or manipulates fluids by geometrically confining fluids on a small scale (for example, sub milliliter volumes such as microliters, nanoliters, or picoliters). The microfluidic system is capable of transmitting virtually any payload in a cell intracellularly. The system consists of one or more microfluidic channels with a constriction through which cells pass through. Preferably, the cells flow through the microfluidic channel suspended in a liquid medium that is driven by pressure through the system. When a cell passes through the constriction, its membrane is disturbed, which causes temporary breaks in the membrane and results in the retention of the payload that is present in the surrounding media. Constriction is a function of the size of the target cell, but preferably in the same order or less than d the diameter of the cell. Multiple constrictions can be placed in parallel and / or in series. Cell disturbance is a gap in the cell that allows material from outside the cell to move into the cell (for example, a crack, a tear, a cavity, an orifice, a pore, a gap, a gap, a perforation ). Disturbances (for example, pores or cracks) created by methods described in this document are not formed as a result of a set of protein subunits to form a multimeric pore structure such as that created by bacterial complement or hemolysins. Other modalities are within the scope of the described material.
[0096] With reference to FIGS. 1 to 3, a microfluidic system 5 includes a channel 10 that defines a tubular lumen. The microfluidic channel 10 includes a constriction 15 which is preferably configured so that only a single target cell 20 can pass through constriction 15 at a time. Preferably, cells 20 pass through channel 10 suspended in solution buffer 25 which also includes delivery materials 30, although delivery materials can be added to solution buffer 25 after cells 20 pass through constriction 15. While cell 20 approaches and passes through constriction 15, constriction 15 applies pressure (for example, mechanical compression) to cell 20, which squeezes cell 20 (for example, shown as cell 20i). The pressure applied to the cell by constriction 15 causes disturbances (for example, cracks shown in FIG. 4) in the cell membrane (for example, cell 202). Once the cell passes through the constriction 15, the cell 20 begins to retain the material in the solution buffer 25 through the slits, which includes the delivery material 30 (for example, cell 203). The cell membrane recovers over time and at least a portion of the delivery material 30 preferably remains trapped within the cell.
[0097] The configuration of constriction 15 can be customized to control the constriction of cell 20, thereby controlling the pressure applied to cell 20. Preferably, constriction 15 includes an inlet portion 35, a central point 40 and a portion outlet 45. For example, the diameter (s) of constriction 15 can be varied to adjust the pressure applied to the cell (and how quickly that pressure is applied / released) and the length of constriction 15 can be varied to adjust the amount of time that pressure is applied to the cell. In certain configurations, physical constriction of the cell is not required; instead, subjecting the cell very briefly to a shear rate and / or an exceptionally high compression rate can cause the desired disturbances. In general, there is no requirement for the outer diameter of the microfluidic system and the ratio of the inner diameter to the outer diameter can be varied (for example, greater than 5).
[0098] The diameter of the central point 40 can be a function of the diameter of cell 20. Preferably, the central point 40 is in the same order as or is less than the diameter of cell 20 (for example, 20 to 99% of the diameter cell). Preferably, the diameter of the center point 40 is between 60% and 70% of the diameter of the cell, although an optimal center point diameter may vary based on the application and / or the type of cell. Exemplary diameters of the central point 40 that were used in previous experiments are 5 to 6pm, and 7 to 8 pm. The center point 40 can also be longer than the diameter of cell 20, but be configured to cause a pressure pulse (for example, shear) that is applied to cell 20. Such pressure can be applied to cell 20 without touching the channel 10 walls. Shear can be measured by known techniques (for example, Journal of Applied Physics 27, 1097 (1956); Murphey et al.).
[0099] The constriction angle (for example, that in FIG. 2A) of the inlet portion 35 can vary (for example, how fast the diameter decreases). The constriction angle is preferably an angle that minimizes clogging of the system 5 as cells pass through it. The angle of the outlet portion 45 can vary in the same way. For example, the angle of the outlet portion 45 is configured to reduce the likelihood of turbulence / eddies that can result in non-laminar flow (for example, a range of 1 to 80 degrees). The walls of the inlet portion 35 and / or the outlet portion 45 are preferably linear, although other configurations are possible (for example, the walls can be curved).
[00100] The cross section of channel 10, the input portion 35, the central point 40, and the output portion 45 can vary. For example, the various cross sections can be circular, elliptical, an elongated slit, square, hexagonal, triangular, etc. The length of the center point 40 can also vary, and can also be adjusted to vary how long pressure is applied to cell 20 as it passes through constriction 15. At a given flow rate, a longer constriction 15 (for example , a longer center point 40) will apply pressure to cell 20 for a longer period of time. The depth of channel 10, inlet portion 35, center point 40 and outlet portion 45 can vary. For example, the depth can be adjusted to provide a tighter constriction and thereby enhance delivery in a manner similar to changes in the width of the constriction. The width and length vary between device designs and can be determined during the manufacture of the device, such as by a chrome mask used in a lithography step (when the device is based on silicon). The depth can be uniform throughout the entire channel and can be determined during the manufacture of the device, such as by a step of deep reactive ion engraving. The depth can be, for example, 15pm to 20pm. As used in this document, device dimensions are indicated by a series of numbers indicating length, width and number of constrictions (for example, 30pm to 6mx5 indicates a device with a length of 30pm, a width of 6pm, and 5 constrictions ).
[00101] The speed at which cells 20 pass through channel 10 can also vary to control the delivery of delivery material 30 to cells 20. For example, adjusting the speed of cells 20 through channel 10 can vary the amount of time that pressure is applied to the cells and can vary how fast the pressure is applied to the cell (for example, slowly or in shock). Cells 20 pass through system 5 at a rate of at least 0.1 mm / s such as 0.1 mm / s to 5 m / s, and preferably between 10 mm / s to 500 mm / s, although other speeds are possible. In some embodiments, cells 20 can pass through system 5 at a rate greater than 5 m / s.
[00102] Channel 10 can be manufactured from various materials such as silicon, glass, ceramics, crystalline substrates, amorphous substrates and polymers (for example, Polymethyl methacrylate (PM-MA), PDMS, Cyclic Olefin Copolymer) (COC), etc.). Manufacturing is preferably based on a clean room and can use, for example, dry engraving, wet engraving, photolithography, injection molding, laser ablation, SU-8 masks, etc. An exemplificative channel 10 is approximately 40 to 50 pm, which has a non-constricted diameter of approximately 50 pm, which has a constricted diameter of approximately 4 to 8 pm. Preferably, the length of channel 10 is kept short to avoid clogging. Other dimensions are possible.
[00103] FIG. 39 depicts another modality of the microfluidic system. In this embodiment, channel 10 includes a preliminary input portion 50 that does not constrict cell 20. An expanded channel portion 55 provides input portion 35 to have a 90 degree constriction angle (for example, alpha in FIG. 2A ).
[00104] FIGS. 40A and 40B are two actions that show a comparison of viability and efficiency of delivery between two examples of modalities. The 4000 label designates measurements taken while using a modality in accordance with FIG. 2A while 4010 designates measurements taken while using a modality in accordance with FIG. 39. At the same operating speed and pressure as the cell, FIG. 39 has shown high delivery efficiency and viability. This occurs despite having shear rates, cell speed and time spent under compression similar to the one in FIG. 2A.
[00105] Several parameters can influence the delivery of delivery material 30 to cell 20. For example, the dimensions of constriction 15, the speeds of operation flow (for example, transit time from to constriction 15), concentration of delivery material 30 in solution buffer 25 and the amount of time that cell 20 recovers / incubates in solution buffer 25 after constriction may affect the absorption of delivery material 30 within cell 20. Additional parameters that influence delivery from material 30 to cell 20 may include the speed of cell 20 in constriction 15, the shear rate in constriction 20, the velocity component that is perpendicular to the flow velocity, a cell compression ratio and time in constriction . Such parameters can be designed to control delivery of delivery material 30. The composition of solution buffer 25 (eg, salt concentration, serum content, etc.) can also impact delivery of delivery material 30. While cell 20 passes through constriction 15, the deformation / stress induced by constriction 15 temporarily injures the cell which causes passive diffusion of material through the disturbance. In some embodiments, cell 20 is deformed only for a brief period of time, in the order of 100 ps to minimize the chance of activating apoptotic pathways through cell signaling mechanisms, although other durations are possible (for example, which varies from nanoseconds to hours). Initial observations indicated that absorption of delivery material 30 by cell 20 occurs in the order of minutes after cell 20 passes through constriction 15.
[00106] Cells 20 can be conducted through channel 10 by various methods. For example, a pressure can be applied by a pump on the inlet side (for example, gas cylinder, or compressor), a vacuum can be applied by a vacuum pump on the outlet side, capillary action through a tube and / or system 5 can be powered by gravity. An offset based on flow systems can also be used (for example, syringe pump, peristaltic pump, hand syringe or pipette, pistons, etc.). Exemplary flow rates through a single channel 10 are on the order of 1p in a few seconds. In addition, solution buffer 25 may include one or more lubricants (pluronic or other surfactants) that can be designed to reduce or eliminate clogging of channel 10 and improve viability.
[00107] System 5 can be controlled to ensure that delivery quantities of delivery material 30 are consistent across the cell population. For example, system 5 may include the use of a post-constriction convective delivery mechanism that collides the delivery material 30 on the permeabilized cell membrane of cell 20. By controlling the flow rate of the secondary current, the amount of material delivery 30 supplied to the cell can preferably be controlled. In addition, controlling the concentration of delivery material 30 in solution buffer 25 during membrane re-recovery can also improve the consistency of delivery of delivery material 30 to the cell population. Preferably, system 5 operates purely as a mechanical system without applying any electrical fields and / or chemical agents, although other configurations are possible (for example, electrical and / or optical sensors can be used to measure cell properties such as fluorescence). Additionally, system 5 preferably operates regardless of the type of material that is transmitted. For example, proteins, RNA, and DNA can be transmitted through the same system without any further modifications.
[00108] In some configurations with certain types of cells 20, cells 20 can be incubated in one or more solutions that assist in absorbing the delivery material into the cell. For example, cells 20 can be incubated in a de-polymerization solution such as Latrunculin A (O.Ag/ml) for 1 hour before delivery to depolymerize the actin cytoskeleton. As an additional example, cells can be incubated in 10 µM Colchicine (Sigma) for 2 hours before transmitting to depolymerize the microtubule network. These methods can help to obtain gene expression when transmitting DNA.
[00109] Referring also to FIG. 5, a photograph of a parallel configuration of the system 5 is shown. System 5 can include any number of parallel channels. Preferably, as additional parallel channels are added to system 5, the overall throughput of system 5 can be increased. FIG. 6 shows a configuration of the constriction 15 that includes an inlet portion 35 that includes multiple steps. Referring also to FIG. 7, an additional photograph of a system 5 prototype is shown. As evident in FIG. 7, the prototype, which includes an incubation well, is approximately 2.5400 centimeters (1 inch) x 0.63500 centimeters (0.25 inches) x 0.63500 centimeters (0.25 inches). Other configurations of system 5 may also include classifiers, pre-treatment / post-treatment modules, and / or sensor modules (for example, optical, electrical and magnetic).
[00110] As described in more detail below in relation to the examples, the microfluidic system and related methods have a wide range of applications. FIG. 42 is an illustration that depicts several examples of fields of application. For example, current material can be applied to regenerative medicine such as to enable cell reprogramming and stem cell differentiation. The current subject can be applied to immunology such as for presenting antigens and enhancing / suppressing immune activity through delivery to dendritic cells, monocytes, T cells, B cells and other lymphocytes. In addition, imaging and sensing can benefit from improved delivery to target cells of quantum dots, carbon nanotubes and antibodies. Additionally, the current article has application in cancer vaccines and research, such as for isolation of circulating tumor cells (CTC) and treatment of Lymphoma. The method also provides a robust platform to search for active siRNA and small molecule compounds capable of treating a disease or manipulating cell behavior.
[00111] This concept was successfully demonstrated in a prototype where 20 cells were induced to assume an impermeable membrane dye (for example, fluorescent dyes from 3kDA to 2MDA) in molecular weight, DNA, protein, RNA, nanotubes or nano particles present in solution buffer 25. Cells 20 have been shown to recover and proliferate after the process while retaining the transmitted material for more than 72 hours. Eleven different cell types were tested with this system, including those listed in FIG. 33, which consequently demonstrates that the system provides robust performance in different cell types. FIG. 33 is a table that includes cell types that current material has been successfully applied to. Average cell yield was measured on the order of 5,000 to 20,000 cells / second, standard delivery efficiency was measured at 96% and cell viability was measured at 95% using a single channel 10. All tests were performed at room temperature. The temperature, however, may have varied in some techniques. For example, methods can be performed at room temperature (for example, 20G), at physiological temperature (for example, 39G), at a temperature higher than physiological, or at reduced temperature (for example, 4G), or at temperatures between these exemplary temperatures. Performing the methods at a reduced temperature (that is, substantially close to 4G that can be achieved, for example, using refrigeration, ice bath or other known techniques) produced a surprising improvement in delivery efficiency and cell viability. In this way, the temperature can be adjusted to affect cell composition and viability delivery.
[00112] As shown in FIGS. 8a-b, increasing the speed of the cell through constriction 15 can increase the percentage of delivery and the delivery efficiency of the delivery material 30. It has been found that the delivery efficiency varies linearly with the speed of the cell and that there was a dose-dependent response.
[00113] As shown in FIG. 9, the incubation time of a cell in solution buffer 25 after the cell passes to constriction 15 can have an effect on the percentage of overall delivery of delivery material 30 to cell 20. It was observed, however, that after a certain amount of incubation time (approximately 2 to 3 minutes), the percentage of delivery was substantially unchanged. Based on these data, it is believed that the disturbances caused in cell 20 after it passes through constriction 15 are corrected within the order of about five minutes after cell 20 passes to constriction 15. Additionally and by reference, -1 minute corresponds to the control group.
[00114] As shown in FIG. 10, it was observed that passing cells 20 through constriction 15 multiple times can have an effect on the percentage of overall delivery, but that it negatively affected the general viability of cells 20. To generate this data, cells were passed through constriction 15, collected and passed through the device again within approximately 1 minute.
[00115] It has been observed that during the time that cells 20 are disturbed (for example, after passing through constriction 15), the material inside the cell can be extracted through the disturbances. In this way, it was discovered that when cells 20 are disturbed, that a material can flow in and out of cell 20. This properly means that system 5 can be used as a method of taking samples of intracellular material without causing cell lysis in the cell. Disturbances in the cell membrane will preferentially result in a flow of macromolecules from the cytoplasm and thus can be used to probe the cytoplasm composition.
[00116] As shown in FIG. 11, stable green fluorescent proteins (GFP) that express HeLa cells were treated in the presence of siRNA that silences GFP (Ambion, US A) and analyzed by FACS (FACS Canto II, BD Biosciences, USA) in 48 hours for shedding of fluorescence. The results in FIG. 11 indicate a shedding> 40% of gene expression - a result comparable to that of commercial agents such as Lipofectamine 2000 (Invitrogen, U.S. A). Mixed siRNA controls, also in FIG. 11, indicate that this drop is not caused by the deformation process itself.
[00117] As shown in FIGS. 13-14 and, the dimensions of the sizing may have an effect on the overall delivery efficiency of the delivery material 30. For example, FIGS. 13-14 show that while operating pressure is varied (for example, varying the length and / or width of the constriction 15) the overall delivery efficiency varies slightly (FIG. 14 relates to the delivery of quantum dots (nano particles) under different conditions). In addition, as shown in FIGS. 18a-18b, the estimated speed of the cells may have an effect on the overall delivery viability and efficiency of the delivery material 30. For example, FIG. 18a shows that while the speed of operation is varied, the overall delivery efficiency varies slightly. Additionally, FIG. 18b shows that while the operating speed is varied, the viability of the cells may vary slightly. These FIGS show that a change in constriction length can enhance delivery while minimally impacting viability. Additionally, larger molecules enter the cell at a lower rate after constriction than smaller molecules. This delivery method described in this document is “universal” in that it works for many different types of materials and cells. In addition, membrane breaks induced by this device can typically be at least -100 nm in size, although other size breaks are possible.
[00118] With reference to FIG. 12, in one implementation, the concentration gradient between solution buffer 25 and the cytosol can be controlled to predictably control the amount of material transmitted. Localized delivery methods that expose cells 20 to a concentrated cloud of macromolecules after the cells 20 have been put through the constriction can be used. Any such method of localized delivery, however, must account for the estimated time to reseal the disturbance to ensure proper function. This can be implemented by incorporating a “micro nozzle” perpendicular to the channel that transmits a high concentration of the payload to the proximity of the cell membrane (illustrated in Figure 6A). Preferably, the micro nozzle can be located at and / or close to the constriction 15. Such an approach could allow supplementation of the diffuse delivery mechanism with a convective component, thereby enabling more accurate cell loading at higher concentrations. The injection preferably takes place while the cell 20 is in a high concentration area of the constriction 15. A localized technique has the additional advantage of conserving valuable delivery materials because then it is not necessary to maintain a high concentration throughout the entire buffer.
[00119] With reference to FIG. 16a, a series of micropylons 100 can be used to apply pressure to the cells 20 so that a disturbance is caused. In this implementation, cells 20 are forced through an arrangement of constricting pillars in such a way that pressure is applied to cells 20.
[00120] With reference to FIG. 16b, compression plates 105 can be used to apply pressure to cells 20 so that a disturbance is caused. In this implementation, the compression plates 105 can be controlled so that pressure is applied to the cells 20 for a predefined amount of time. The compression plates 105 can be configured so that one or both plates move to apply pressure to cells 20. An additional set of compression plates 105 can also be provided so that cells 20 are substantially surrounded.
[00121] With reference to FIG. 16c, buffer additives 115 (or bulky materials attached to the cell surface) can be used to simulate squeezing while cell 20 passes through a constriction 15 that is larger than the diameter of cell 20. For example, simulated constriction due to interference from buffer 115 additives is possible. Examples of buffer additives 115 include micro or nano particles (for example, based on polymer, based on lipid, based on ceramics, metals, etc.). These particles are labeled with a cell-binding ligand such as an antibody, a DNA sequence, a peptide or a small molecule, although it is not required.
[00122] With reference to FIG. 16d, beads 120 can be used to compress cell 20. For example, magnetic and / or electrostatic force can be used to apply pressure to cell 20, or in the case of FIG. 16e, to pull the cell 20. Preferably, the force applied to the cell 20 is sufficient to cause a disturbance.
[00123] With reference to FIG. 16f, multiple fluid streams 125 can be directed in such a way that the compression (or rapid transient shear) of the cell 20 is caused. For example, multiple streams of fluid 125 can be driven in such a way that they approach or collide with each other. As cells 20 pass through multiple streams of fluid 125, a force can be applied to cells 20 so that a disturbance in the membrane of cell 20 is caused. Alternatively, the cells can be driven through a narrow crack-type nozzle to facilitate delivery.
[00124] System 5 can be an independent system, such as that shown in FIG. 7, although other configurations are possible. For example, system 5 can be implanted in vivo in a patient for local intracellular delivery and or be incorporated ex vivo into a cell treatment machine before returning the cells to the patient.
[00125] In addition to the delivery advantages described in this document, the microfluidic nature of the system allows an individual to exercise precise control over delivery conditions, pre-treatment and subsequent characterization of cells. For example, the system can be implemented in series with a Fluorescence Activated Cell Classification (FACS) module. This can enable delivery and classification of desired cells in the same system, in real time. Various pre-treatments and post-grading assessment techniques can also be employed, which in turn enables the development of continuous high-throughput assessments for drug screening and diagnostics.
[00126] The efficiency of delivering a payload delivered to target cells is determined by subjecting a target cell control population to a payload as well as a population that has been treated by a microfluidic device. The control sample is exposed to the same delivery solution, in the same concentration, for at least the same amount of time as the cells treated by the device. To compensate for surface binding, endocytosis, and other effects such as autofluorescence, a delivered region is defined so that only the top 1 to 5% of live control cells are in that region. The delivery efficiency of a sample thus corresponds to the percentage of live cells that are in the delivered region. For example, FIG. 43A is a histogram of flow cytometry intensity of a control population that is exposed to blue cascade conjugated 3KDa dextran. FIG. 43B is a histogram of flow cytometry intensity of cells that were subjected to a device from 30pm to 6 pm. The defined delivered region is the region not shaded in both 43 A and 43B.
[00127] In operation, with reference to FIG. 17, in further reference to FIGS. 1-3, a process 1000 for performing intracellular delivery to system 5 includes the stages shown. Process 1000, however, is exemplary only and not limiting. Process 1000 can be changed, for example, by having stages added, removed, changed, or redeployed.
[00128] In stage 1005, cells 20 are buffer solution 25 suspended with delivery materials 30. Typical cell concentrations can be in the range of 104 to 109 cells / ml. Concentrations of delivery material can be in the range of 10 mg / ml to 0.1 mg / ml. The delivery material can be added to the buffer cell before or immediately after delivery depending on the desired configuration as the lesions / pores remain open for 1 to 5 minutes. Buffer solutions can be composed of a series of salts, sugars, growth factors, products derived from animals or any other component necessary for appropriate cell proliferation, maintaining cell health or inducing cell signaling pathways. Additional materials can also be added to buffer 25. For example, surfactants (for example, pluronics) and / or bulky materials can be added to buffer 25.
[00129] In stage 1010, buffer solution 25 which includes cells 20 and delivery materials 30 is passed through channel 10 of system 5. The buffer solution 25 can pass through channel 10 with the use of gravity, or be assisted by other methods. For example, pressure can be applied to buffer solution 25 on the inlet side of channel 10 (for example, using a gas cylinder and / or compressor), and / or a vacuum can be applied by a pump vacuum on the outlet side. In addition, displacement-based flow systems can also be used.
[00130] As individual cells 20 pass through constriction 15, pressure is momentarily applied to cell 20 by the solid construction of constriction 15 causing disturbances such as holes to develop in the cell membrane so that delivery materials 30 can be delivered inside cell 20. The amount and / or duration of pressure applied to cell 20 can be varied by adjusting the dimensions of the constriction 15, the speed at which the cell 20 passes through the constriction 15, and / or adjusting it if the shape of the constriction 15. In one configuration, approximately 5,000 to 20,000 cells / second pass through the constriction 15, and each cell is constrained to approximately 100 ps.
[00131] System 5 can include one or more of channels 10. For example, system 5 can include 50 to 100 of channels 10 which are arranged in a parallel configuration. The use of a parallel configuration can reduce the consequences of an obstruction development in one or more of the channels 10, and can increase the overall throughput of system 5. Additionally, system 5 can include one or more of the channels in series one with the other.
[00132] In stage 1015, after cells 20 pass through constriction 15, cells are allowed to incubate / recover by sitting in buffer 25. During that time, cells 20 will capture some of the delivery materials 30 present in buffer 25 through disturbances in the cell membrane. A capture mechanism is based on diffusion, due to the fact that larger molecules appear to be absorbed at a lower rate than smaller molecules. Preferably, cells 20 are allowed to incubate / recover in buffer 25 for 2 to 5 minutes, although other durations are possible. During the time that cells 20 are incubating / recovering in buffer 25, material inside cell 20 can also be released from the cell to buffer 25. During the incubation / recovery period, certain conditions can be controlled to ensure that delivery quantities of delivery materials 30 are consistent across the cell population. For example, post-constriction, convective delivery mechanisms that collide delivery material with the incubation / recovery cell can be used.
[00133] Optionally, in stage 1020, after the cells have been incubated / recovered, the cells can be washed to remove the buffer solution. Preferably, washing occurs after the time required for the disturbances to be repaired, although washing may occur at other times in order to control the amount of delivery materials 30 absorbed by the cells. Example 1 - Delivery of functional manipulated nanoparticles
[00134] The manipulated nanomaterials have immense potential as a tool for imaging living cells, therapeutic molecular delivery agents, or even as ways to manipulate living cells with external means such as light or magnetic fields. (Howarth, M., et al. Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nature Methods 5, 397 to 399 (2008)). However, many of these potential applications require that nanomaterials be delivered to the cell cytosol. Most nanoparticles, such as QDs, need to be passivated with a polymer that makes the nanoparticles soluble in aqueous media, and this generally prevents them from passively diffusing through the cell membrane. Micro-injection of nanoparticles is considered impractical due to the requirement for specialized equipment and low flow rates while electroporation causes the aggregation of QD within the cell. Therefore, the majority of attempts to deliver QDs to the cell cytoplasm were based on QDs being endocytosed by the cell and shedding the endosome. Before the current article, it was not possible to deliver QDs to the cell cytoplasm in a satisfactory and scalable way. Your system provides a solution to this delivery system from previous approaches.
[00135] The microfluidic device is combined with a new generation of biologically compatible QDs recently described. (Liu, W., et al. Compact biocompatible quantum dots by means of RAFT-mediated synthesis of imidazole-based random copolymer ligand. JACS 132, 472 to 483 (2010)). The QDs used throughout Example 1 were coated with a polyimidazole binder comprised of multiple metal chelating imidazole groups and multiple water solubilization passivating poly (ethylene) glycol (PEG).
[00136] For delivery of cytosolic QDs, the cells were aliquoted in a PBS solution containing QD. The cell QD solution was pipetted into the microfluidic device and the solution was driven through the channels at constant pressure, followed by an incubation period of 5 min. After this incubation period, excess QDs were separated by centrifugation. For the control population, the cell QD solution was placed in the microfluidic device and the cells were exposed to the QD solution for an amount of time equivalent to the cytosolic delivery protocol.
[00137] FIG. 19 is a delivery layer and confocal fluorescent images, followed by confocal fluorescent images of section Z of treated cells delivered with QDs using the current material. FIG. 19 illustrates (top) immediately after treatment (i.e. delivery) and (bottom) after 48 h of incubation at 37 ° C and 5% CO2. The diffuse spot pattern is restricted to the cytoplasm and the nanoparticles do not appear to enter the nucleus (dark region within the cell). The scale bar is 10 pm. The particular free polyimidazole binder that coated the QDs imaged in FIG. 19 had no functionality except for providing biocompatibility through PEG groups. Confocal microscopic images show that HeLa cells, detached and rounded after flowing through the microfluidic device, have diffuse cytoplasmic QD stain in all the different Z sections of the cell (FIG. 19, top). The diffuse stain persists even after 48 hours, following the incubation and adherence of the cells at 37 ° and 5% CO2 (FIG. 19, background). Diffuse QD fluorescence is cloudy at 48hrs, probably due to cell division (FIG. 19). QDs delivered by devices (hydrodynamic diameter of -13 nm) in -40% of the population of living cells at a flow rate of -10,000 cells / s. FIG. 20A illustrates the efficiency of delivery in HeLo cytosol cell by treating current material with PIL coated QDs. Cell viability was> 80% as measured by flow cytometry. FIG. 20B illustrates the viability of HeLa cells by delivering flat QD535 to the current material, as measured by propidium iodide stain and flow cytometry measurement. The viability of treated cells as measured by flow cytometry, the diffuse spot in the confocal images, and the cell's adherence capacity are consistent with the delivery of QDs to the cytoplasm of a living cell.
[00138] To confirm that fluorescence does appear from QDs delivered to the cytosol as opposed to QDs sequestered in endosomes, the nanoparticle was designed to change its emission profile through interaction with the cytosol-reducing environment. The reduction potential within the cell cytoplasm is -260 to -220 mV and is primarily dictated by maintaining high concentrations (5 to 10 mM) of tripeptide glutathione. Therefore, by measuring the fluorescence of a QD dye construct whose emission changes when exposed to the cytosolic environment, the location and chemical accessibility of the delivered nanoparticles can be determined. A QD dye was constructed comprising a green emission QD (Remission = 541 nm) that acts as an energy donor to a carbon-x-rhodamine dye (Rox) (Remission = 610 nm), conjugated through a reducible disulfate bond.
[00139] FIG. 21 illustrates construction design, absorption, and stability in various media. In 2100 it is a scheme of the PIL before conjugation with the dye and coating of the QDs (left), and the resulting construct of QD-disulfide-Rox (right) (image out of scale). In 2110 is the absorption spectrum of the QD-disulfide-dye construct. Excitation at 488 nm and 405 nm provided exclusive absorption by QDs throughout the experiment. In 2120 it is the stability of fluorescence energy transfer from QD to Rox to the construct in the total culture media at 3713 and 5% CO2, which demonstrate that the disulfide bond is not cleaved in the extracellular environment. Diagram 2130 illustrates disulfide bond cleavage by cytosolic reducing glutathione, as shown by QD fluorescence recovery. In 2140, QD fluorescence recovery by treatment with non-thiol reducing tris (2-carboxyethyl) phosphine is shown, further assisting the disulfide bond cleavage.
[00140] The thiol groups that have been incorporated into the disulfide bonds formed from PIL with thiolate Rox dyes. The absorption spectrum of the purified construct has absorption resources in both QD and Rox (2120) in an average of 13 Rox dyes per QD, abruptly and efficiently cooling QD fluorescence (2130). This construct serves as an irreversible sensor of the specific cytosol reduction environment. When the QD is selectively excited by a laser at 488 nm (microscope) or 405 nm (flow cytometry) while the disulfide bridges are intact, the construct undergoes fluorescence resonance (FRET) energy transfer so that the Rox emission in red, be dominant. In a solution assay, cell-reducing glutathione cleaves the disulfide bonds, which release Rox dyes and allow QD fluorescence for recovery (2140). Reducing tris- (2carboxyethyl) phosphine based on non-thiol also allows recovery of QD fluorescence, which indicates that the release of Rox from the QD surface does not occur by displacing PIL by glutathione (2140). Rox fluorescence may not disappear completely due to the sum of the disulfide bonds that are sterically inhibited by large PEG groups in the PIL, and due to a small amount of non-specific interaction between the dye and the QD surface.
[00141] Changes in the fluorescence profile of the construct, as measured by flow cytometry and confocal microscope, confirm the delivery of QD-disulfide-Rox constructs to the cell cytoplasm. When exposed to the cytosolic reducing environment, the cleavage of the disulfide bonds breaks the QT FRET process to the dye. Therefore, through exclusive QD excitation, QD channel fluorescence increases while Rox channel fluorescence decreases over time. The live HeLa cells were treated by the microfluidic device in a solution with a high concentration of QD-disulfide-Rox, incubated for 5 minutes, and washed to remove excess QDs before adding the cell culture media (ie, treated cells ). The control cells were incubated with QD-disulfide-Rox for 5 minutes instead of being treated by the microfluidic device, and washed before being placed in cell culture media. The Rox and QD channel fluorescence of these treated and control cells were observed both by a confocal microscope by flow cytometry.
[00142] FIGS. 22A and 22B illustrate confocal images of a live cell microscope and fluorescence intensity analysis showing cytoplasmic staining and QD surface chemical accessibility. FIG. 22A illustrates images of treated cells (top) and control cells (bottom). The appearance of diffuse green fluorescence is present only in treated cells. The scale bar is 10 pm. FIG. 22B illustrates a change in intensity as a function of time in the green and red channels. Due to the fact that n <20 at each time point, fluctuations in the total mean fluorescence were corrected by normalizing to the 0 h time point.
[00143] Under the confocal microscope, the diffuse fluorescence that appears through the cytoplasm of treated cells progresses from bright red to bright green (as shown in FIG. 22A). Control cell images show some non-specific binding on the outer membrane as demonstrated by the ring-shaped fluorescence, and there is no increase in green channel signals. These effects are consistent with the expected cleavage of cytosolic disulfide bonds that reduce the effect of FRET. In FIG. 22B, the line graph shows the average channel intensity of QD and Rox per cell after correcting cell-cell differences in the fluorescent material delivered, normalizing to full fluorescence, to treated cells and control and autofluorescence. For treated cells, the graph shows a cross between 2 to 4 hours of incubation in which QD fluorescence appears above Rox fluorescence. interestingly, the treated cell Rox signal is shown to settle above autofluorescence levels after 9 hours. This is consistent with the results of the solution tests, in which some FRET remained after the reduction. The observed diffuse spot and increase in QD signal and reduction in Rox signal greatly assists cytosolic delivery and subsequent disulfide binding divage. QD fluorescence in control cells, abruptly cooled by FRET to Rox, appears indistinguishable from autofluorescence. Control cells exhibit some Rox fluorescence above autofluorescence at early points of time, which then decrease immediately. This can be attributed to the non-specific interactions between QD-S-S-Rox and the cell surface, followed by resolvation of the constructs in half.
[00144] FIG. 23 illustrates the measurement of cell fluorescence flow cytometry and viability. At 2300 it is average fluorescence of QD (left) and Rox (right) per cell, which shows an increase in QD fluorescence only in treated cells. Rox fluorescence in both treated and control cells is at autofluorescence levels for the 24 h time point. In 2310 is a histogram of the distribution of fluorescence intensities between the treated cells and control in the selection of time points, in the QD channel (left) and Rox channel (right). QD delivery is estimated to have occurred in at least 35% of the cell population. The green areas are designed to guide the eye in the movement of histogram peaks of fluorescence intensity. In 2320 it illustrates the viability of control and treated cells as measured by propidium iodide.
[00145] The flow cytometry measurements illustrated in FIG. 23 confirm that the QD-disulfide-Rox constructs can interact with the cytosolic environment. Flow cytometry measurements were recorded on all living cells, covering both delivered cells (-35% of the treated cell population) and undelivered cells. In 2100 the average fluorescence per cell of the treated and control populations is illustrated. The mean fluorescence of QD appears initially for the treated cells, reaching the peak in -9 hours and then gradually decreasing, in contrast to the QD fluorescence of the control cell population, which remains comparable to levels of autofluorescence. This is consistent with the cytosolic reduction of disulfide bridges between the QD and the dye within the treated cells followed by the dilution of fluorescence constructs by cell division. Rox fluorescence for both treated and control cells starts high and drops within 2 hours. This drop is attributed to resolvation in the midst of particles that bonded to the cell surface during incubation. The average fluorescence of Rox in the treated cell population appears similar to the control cells due to the presence of undelivered cells within the treated population. The presence of both delivered and undelivered cells within the treated population can be distinguished from the QD and Rox intensity histograms shown in 2310. With increasing time, fluorescence histograms become bimodal for treated cells, but remain unimodal for control cells. QD fluorescence appears over time in a subset of the treated cell population (2100), further assisting the disruption of the FRET process in the cytosol of treated and delivered cells. Rox fluorescence generally decreases as the membrane-bound constructs are resolvated in half, but a subset of the treated cell population retains Rox fluorescence. This is consistent with the incomplete reduction of QD-S-S-Rox bonds observed under a confocal microscope. The viability of the treated cell population, as measured by the propidium iodide stain, is within 10% of the control population at all time points (2130). The cell viability of> 90% compared to the control group compares favorably to alternative methods such as electroporation and polymer-based methods, which yielded post-treatment viability as low as 40 to 60%.
[00146] FIG. 24 illustrates epifluorescence imaging of single non-aggregated QDs within the cell cytosol after device treatment with a 10 nM QD solution (top), and intermittent traces of the three QDs labeled 2400, 2410, and 2420 with autofluorescence. The intermittent QD traces appear to be non-binary due to long acquisition distance times (500 ms). Scale bars are 10 pm.
[00147] The QD distribution platform also enabled single cell imaging by delivering non-aggregated QD-disulfide-Rox constructs, as the emission intermittency observed is consistent with single QDs. For these experiments, QD-disulfide-Rox constructs were delivered to the cytosol followed by a 10-hour incubation and imaged under an epifluorescence microscope. The 10-hour incubation ensured that QD fluorescence from inside the cytosol recovered by disulfide reduction binding; the epifluorescence microscope was used to ensure that enough photons were collected. Several intermittent QDs were observed when cells were treated by the current matter in low QD concentrations (FIG. 24). The intensity traces of QDs in termitent in the cytosol, shown in 2400, 2410, and 2420, seem non-binary as a result of long acquisition distance times (500 ms). Translational cell movements were assessed minimal during the acquisition time frame (~ 1 min). These data demonstrate the ability to observe single molecule events within the cell cytosol by delivering QDs with fluorescent labels using the current material.
[00148] Example 1 demonstrates delivery of nanoparticles in cell cytosol according to a modality of the current matter. Observing the QD-disulfide-Rox cleavage by cytosolic reducers, it was demonstrated that the nanoparticle surface interacts with cytosolic components. The modalities of the current matter allow the delivery of QDs in cell cytoplasm at high flow without any cell penetration or endosome escape ligands, while conserving cell viability and QD integrity. The 35% delivery efficiency can be further increased by increasing the number of microfluidic constrictions, changing constriction dimensions, or by increasing the number of treatment cycles. Unlike most peptides that penetrate the current cell or positive charge-assisted delivery methods, the current matter does not require double conjugation of an intracellular delivery handling and a cytosolic protein target handling in the same nanoparticle. By eliminating the need for the trainer, the mitigation of cross-sensitivity issues, unmatched reactivity efficiencies of conjugation strategies, and stoichiometric conjugation can be achieved. Therefore, significant QD construction design flexibility is achieved, paving the way for intracellular protein labeling and tracking. The methods are useful for the delivery of many fluorescent nanomaterials with complex designs that target intracellular proteins and organisms through proven protein targeting strategies such as, but not limited to, streptavidin-biotin, HaloTag-chloroalkane, and draw marking .
[00149] In example 1, all chemicals were obtained from Sigma Aldrich and used as received unless otherwise indicated, air sensitive materials were handled in an Omni-Lab VAC glove box under a dry nitrogen atmosphere with levels oxygen <0.2ppm. All solvents were spectroscopic or reactive. The compounds that have an aromatic ring were visualized in TLC using a portable UV lamp and KMnO4. compounds that have amine were visualized on TLC using a Ninhydrin stain. Flash column chromatography was performed on a Teledyne Isco Combi Flash Companion. HeLa cells were purchased from ATCC and all cell media materials were purchased from Mediatech unless otherwise noted.
[00150] In example 1, 1H NMR spectra were recorded on a Bruker DRX 401 NMR spectrometer. MS-ESI was performed on a Bruker Daltonics APEXIV 4.7 FT-ICR-MS machine. UV-Vis absorption spectra were taken using an HP 8453 diode array spectrophotometer. The photoluminescence and absorption spectra were recorded with a BioTek Synergy 4 Microplate reader. The molecular weights of polymer were determined in a DMF solution in an HPLC / GPC system from the Agilent 1100 series with three volumes of PLgel (103, 104, 105 A) in series in narrow polystyrene standards. Dye derivatives were purified using the HPLC Varian ProStar Prep system. The modified polymer was purified using GE Healthcare's PD-10 columns packed with SefadexTM G-25M. QDs of exchanged ligands were purified by centrifugation dialysis with Millipore AmiCon Ultra 30K cut centrifugal filters and by GFC in an AKTAprime Plus chromatography system (Amersham Biosciences) equipped with a Superdex 200 10/100 self-packed glass column. Flow cytometry measurements were made at LSR Fortessa (BD Biosciences).
[00151] In example 1, CdSe nuclei with the first 478nm absorption peak were synthesized using a previously reported method (1). To summarize, 0.4 mmol (54.1 mg) of CdO, 0.8 mmol (0.2232g) of TDPA, 9.6mmol (3.72g) of TOPO were placed in a 25ml round bottom flask. The solution was degassed for 1 hour at 1600 and heated to 3000 under argon until the CdO had dissolved and formed a clear homogeneous solution. This was followed by placing the solution under vacuum at 1600 to remove evolved water. The solution was preheated to 3600 under argon and a TOP-Se solution (1.5ml of 1.5M TOP-Se in 1.5ml of TOP) was quickly added to generate CdS nuclei and with the first absorption feature at 478nm.
[00152] CdS shells were deposited in CdSe nuclei by modifying previously reported procedures (2). Cores isolated by repeated precipitations of hexane with acetone were brought to IδO'C in a mixture of oleylamine (3 ml) and octadecene (6 ml), precursor solutions of Cd and S were then introduced continuously at a rate of 4 ml / hr. The precursor Cd consisted of Cd-oleate with 0.33 mmol and oleylamine with 0.66 mmol in a mixture of octadecene solvent (1.5 ml) and TOP (3 ml). Precursor S consisted of hexamethyldisilatian with 0.3 mmol [(TMS) 2S] in 6 ml TOP. The addition of a total of 3 monolayers each of Cd and S yielded QDs with emission at 541 nm and a quantum yield of 60% when diluted in octane. The CdSe extinction coefficient (CdS) was calculated using the literature's CdSe extinction coefficient (3) and assuming that 95% of the CdSe nuclei were retained during the overcoating stage.
[00153] In example 1, the silicon chip was manufactured using photo lithography and deep reactive ion notching techniques. The resulting notched silicon blade was cleaned (with H202 and H2S04) to remove debris, oxidized to produce a glass surface, and attached to a Pyrex blade before being diced in individually packaged devices. Each device was then individually inspected for defects before use. Example 2 - Delivery of Macromolecules
[00154] Delivery of intracellular macromolecules is a crucial stage of therapeutic and research applications. The nanoparticle-mediated delivery of DNA and RNA, for example, is useful for gene therapy, while protein delivery is used to affect cell function in both clinical and laboratory definition, other materials, such as small molecules, quantum dots, or gold nanoparticles, are delivered to the cytosol for purposes ranging from cancer therapies to intracellular labeling and single molecule tracking.
[00155] To demonstrate the versatility of the technique, model dextran molecules were delivered to several cell types: dendritic cells DC2,4, newborn human foreskin fibroblasts (NuFF) and mouse embryonic stem cells (mESC) obtained efficacy of delivery of up to 55%, 65% and 30% respectively. Initial experiments also showed successful delivery of primary lymphocytes, macrophages and dendritic cells derived from mice. Furthermore, the technique did not cause excessive cytotoxicity or induce stem cell differentiation. In fact, all cell types were over 60% viable even at the highest speeds tested. The device design and operating conditions have not previously been optimized for any of the cell types mentioned above.
[00156] FIG. 25 illustrates experimental results that show that delivery performance depends on cell speed and constriction design. The constriction dimensions are indicated by numbers (for example, 10 pm-6pmx5) so that the first number corresponds to the constriction length, the second to the constriction width and the third (if present) to the number of series constrictions per channel. In 2500, delivery efficiency is shown and in 2510 cell viability 18 hours post-treatment (measured by flow cytometry) is shown as a function of cell speed for device designs from 40pm to 6pm (o), 20pm at 6pm (□) and 10 pm- 6pmx5 (Δ). At 2520, delivery efficiency and 2530 cell viability (measured by flow cytometry) is shown as a function of velocity in primary human fibroblasts (□), DC2.4 dendritic cells (o), and embryonic rat stem cells (mESC ) (Δ) handled by a device from 30pm to 6pm device. Human fibroblasts and dendritic cells were analyzed 18 hours after delivery. MESCs were analyzed 1 hour post-delivery. All data points were performed in triplicate and error bars represent two standard deviations.
[00157] FIG. 26 illustrates 2600 scans of different horizontal planes of a HeLa cell after delivery of Pacific blue conjugated 3kDa dextran, as measured by the confocal microscope. Sweeps read from top to bottom, then left to right where the top left is at <= 6.98pm and the bottom right is at = = - 6.7pm. Scale bar represents 6pm. At 2610, live cell delivery efficiency of devices from 10pm to 6pm (□), 20pm to 6pm (o), 30pm to 6pm (Δ), and 40pm to 6pm (0) is shown. The geometric time axis indicates the amount of time that elapsed from initial cell treatments before they were exposed to the target delivery solution. All results were measured by flow cytometry 18 hours after treatment. In 2620, average intensity of the delivered cell population normalized by untreated cells to control autofluorescence. 70kDa dextran conjugated to fluorescein (horizontal lines) and 3kDa dextran conjugated to pacific blue (diagonal lines) are delivered to the cell (cycles 1 and 3) and removed from the cell (cycle 2) in consecutive treatment cycles. The control represents cells that were only exposed to the solution delivery and not treated by the device. All data points were performed in triplicate and error bars represent two standard deviations.
[00158] As the previous delivery techniques based on no-particle and cell-penetrating peptide (CPP) explain endocytotic trajectories, evidence is presented that rules outside the influence of endocytosis on the delivery mechanism of real matter. FIG. 26 illustrates in 2600 confocal microscope cells treated with Pacific blue 3kDa dextran demonstrate diffuse cytosolic stain as opposed to the punctuated characteristic, as would be expected from endocytotic methods. In addition, when delivery experiments are conducted at 4 ° C, a temperature at which endocytosis is minimized, delivery efficiency is minimally affected by the temperature of both test payload materials, 3kDa and 70kDa dextran. These data indicate that endocytosis is unlikely to be responsible for delivery in these systems.
[00159] Delivery kinetics over time has been characterized. The cells were treated with current material in the absence of delivery material and subsequently exposed to pacific blue 3kDa dextran at defined post-treatment time intervals. in this approach, that cells pass through the constriction, their membrane is broken; however, no measurable delivery occurs until they are exposed to labeled dextran. Thus, the efficiency of delivery at each point of time would reflect the proportion of cells that remained porous for that amount of time after treatment. This method captures pore formation / closure kinetics. The results indicate that almost 90% of delivery occurs within the first minute after treatment regardless of the device design (2610). The observed time scale assists the hypothesis of pore formation as previously worked on the membrane repair kinetics reported membrane sealing that occurs about 30s after an injury is induced. In contrast, the recommended time scale for endocytotic methods such as nanoparticle-mediated delivery mechanism and CPP is in the order of hours.
[00160] Since the delivery of material through the membrane pores is diffuse, the material could be exchanged in and out of the cell throughout the life of the pore. Endocytotic or convective mechanisms, on the other hand, need to be unidirectional, that is, they only facilitate the transport of material to the cell. To demonstrate bidirectional transport of material across the cell membrane, an experiment was conducted that consists of 3 delivery cycles. In the first cycle, cells were treated in the presence of 3kDa and 70kDa dextran, incubated for 5 min in the dextran solution and washed twice with PBS. A third of the sample was retained and laminated for follow-up. In the second cycle, the remaining washed cells were treated by the device again, but in the absence of any delivery material and incubated for another 5 min. Half of this sample was rolled for follow-up. In the third cycle, the remaining cells from the second cycle were run through the device under the same conditions as the first cycle (that is, in the presence of dextran), incubated for 5 minutes and washed twice in PBS. The cells were analyzed by flow cytometry 18 hours after the experiment. Changes in the normalized fluorescence intensity demonstrated a net diffusion of dextran to the cells during the first cycle, outside the cells during the second, and back during the third (2620). These results are therefore consistent with the diffuse delivery mechanism.
[00161] FIG. 27 illustrates a simplified 2D diffusion model developed in a software package known as COMSOL Multifysics that simulates passive diffusion of material in a cell through a porous membrane. COMSOL Multifysics is a finite element analysis, solver and simulation software / FEA software package developed by COMSOL for various physics and engineering applications, specially coupled phenomena, or multiphysics. In 2700, material delivery / loss is shown as a function of the diffusion capacity of the membrane. The simulation results that indicate the percentage of material delivered / lost from the cell as a function of membrane diffusivity when the material of interest is in the buffer (□) or in the cell (o) at the time of poration. In 2710 there is a graphical representation of the simulated system and the concentration gradient that forms across the membrane if the material is delivered from the buffer to the cell.
[00162] Using the literature values for particle diffusivities inside and outside the cell cytoplasm, the experiments / results of FIG. 26 were qualitatively recreated with diffusion as the only mode of mass transfer. Furthermore, adapting the experimental data to this model, this technique delivers 10 to 40% of the delivery material in the buffer to the cell cytosol. By comparison, CPP methods for protein delivery are estimated to deliver only 0.1% of the buffer material to the cytosol.
[00163] A particle size (or hydrodynamic ray) affects its diffusivity and its ability to enter membrane pores of a particular size. Thus, this parameter affects the delivery efficiency in the pore formation / diffusion mechanism. In a series of experiments, test payloads of 3kDa, 10kDa, 70kDa, 500kDa, and 2MDa fluorescein or Pacific blue conjugate were delivered. Fluorescein-labeled plasmids estimated at 3.1 MDa were also delivered. These model molecules were selected based on their similar molecular weight for delivery materials of interest. 3kDa-10kDa dextran, for example, are similar in size to some short peptides or siRNA, while the range of 70kDa to 2MDa simulates the size of most proteins and some small nanoparticles.
[00164] FIG. 28 illustrates results of material delivery at two scales. In 2800, the efficiency of live cell delivery, as a function of speed, for HeLa cells treated with dextran 3kDa (□) conjugated to Pacific Blue, 70kDa (o) conjugated to fluorescein and 2MDa (Δ) is shown. This experiment was conducted with a 10 pm-6pmx5 chip. All data points were performed in triplicate and error bars represent two standard deviations. 2810 and 2820, illustrate histogram layers of flow cytometry data for HeLa cells that are untreated (red), treated at 700mm / s (green), treated at 500mm / s (orange), treated at 300mm / s (light blue) ), or only exposed to the delivery material (control, dark blue). The delivery material consisted of pacific blue conjugated 3kDa dextran (2810) and fluorescein conjugated 70kDa dextran (2820).
[00165] The experiments showed that molecules larger than 70kDa have a different delivery profile compared to dextran 3kDa (2800). The device produced a two-scale delivery in which a 10 pm-6pmx5 device operated at 500mm / s, for example, allows over 90% of living cells to receive 3kDa molecules, while about 50% receives molecules larger than 70kDa and 2MDa.
[00166] The histograms corresponding to these flow cytometry data indicate that the delivery of 3kDa dextran produces two distinct peaks (2810). In the first subpopulation, cells exhibit mild levels of delivery as seen by a peak change from controls (account for controls for endocytosis and surface binding as previously described for 0 mm / s data points) with a 2- 6x medium fluorescence intensity. In the second population, cells exhibit marked levels of delivery corresponding to a 20 to 100x increase in average fluorescence intensity compared to controls. This effect may indicate that the last subpopulation of cells was laid more severely than the former, thus allowing an increase of almost 10x material influx. In fact, as illustrated by the 300mm / s, 500mm / s and 700mm / s curves, increasing the severity of treatment, increasing operational speeds, seems to increase the proportion of cells with marked delivery. A similar characteristic is observed for the delivery of larger molecules of dextran 70kDa (2820). The effect is less pronounced, however, as lower particle diffusivity and possible size exclusion effects reduce the overall quantity delivered. The soft delivery population (first peak) shows only an increase of 1.5 to 2x of average fluorescent intensity as compared to the 2 to 6x observed in the case of 3kDa. This effect could consider the discrepancy in the delivery data in 2800 as in the case of larger molecules the soft delivery population could be difficult to distinguish from the controls based on the present definition of delivery. As a result, for larger molecules, such as 70kDa and 2MDa dextran, the second population of pronounced delivery is widely measured
[00167] To verify that the material delivered by rapid mechanical deformation is active and biologically stable in the cell cytosol, a series of experiments were conducted delivering test payload GFP silencing siRNA (Ambion, USA) to HeLa cells that express destabilized GFP. Sequence-specific and dose-dependent GFP silencing (up to 80%) within 18 hours after treatment was observed. The response of gene silencing to cell speed and device design was consistent with dextran delivery experiments so that higher speeds and multiple constriction designs yield higher gene silencing. Lipofectamine 2000 was used as a positive control in these experiments. The device design and operating parameters were not optimized for siRNA delivery before performing these experiments.
[00168] FIG. 29 illustrate data related to the delivery of SiRNA, protein and nanoparticles. In 2900, gene silencing is illustrated as a function of device type and cell velocity in HeLa cells that express destabilized GFP 18 hours after delivery of an anti-eGFP siRNA using a 10 pm-6 pm fragment x 5 at a delivery concentration of 5 pM. Lipofectamine 2000 was used as a positive control. In 2910, the delivery efficiency of 70 kDa dextran identified with fluorescein and 3 kDa identified with pacific blue by rapid mechanical deformation and electroporation is shown. Each type of dextran was at a concentration of 0.1 mg / ml in the delivery solution. In 2920, the delivery efficacy of bovine serum albumin identified with fluorescein (o), delivery efficiency of dextran 3 kDa conjugated by pacific blue (□) and cell viability (Δ) are shown as a function of speed, with the use of a 30 pm-6pm device. At 2930, fluorescent micrographs of HeLa cells immediately after delivery of antibodies to tubulin with a Fluor 488 tag are shown. Scale bars at 5 pm. 2940 and 2950 show images of tunneling electron microscope (TEM) of gold nanoparticles (some indicated by arrows) in cells fixed approximately 1 second after treatment by a 10 pm-6 pmx5 device. Scale bars at 500 nm. All data points were performed in triplicate and the error bars represent two standard deviations.
[00169] In additional experiments, the potential for cytosolic delivery is explored for previously challenging applications, such as protein and nanoparticle delivery. To compare the performance of the present material to commercially available methods, dextran 3 kDa and 70 kDa was delivered, as a protein model, to human fibroblasts using this material and a Neon electroporation system (Invitrogen). The results indicate that rapid mechanical deformation provides a 7-fold or greater increase in delivery efficiency for such macromolecules (2910). To translate the method into protein delivery, a 30 pm-6pm channel diameter device was used to deliver fluorescein-identified bovine serum albumin (BSA) to HeLa cells at up to 44% efficiency while maintaining viability above 90% (2920 ). Antibodies identified with Alexa Fluor 488 to tubulin (Bio Legend) were also delivered to HeLa cells after treatment with a 30 pm-6pm device using an antibody concentration of 0.25mg / ml (2930). Diffuse staining indicates that the material is not trapped in endorsements and, therefore, is suitable for staining antibody in living cells of cellular structures in the cytosol. Apolipoprotein E has also been successfully delivered using this technique.
[00170] For nanoparticle delivery, TEM images of cells fixed approximately 1 second after deformation (2940 and 2950) demonstrate the delivery of coated PEG 1000, 15 nm gold nanoparticles. The gold nanoparticles appear to be mostly unaggregated and have not been visibly hijacked in endorsements. In these images, evidence for various defects in the cell cytoplasm responsible for delivery was observed. High yield has been demonstrated, non-cytotoxic delivery of quantum dots directly to cell cytosol - an objective that previous techniques have difficulty achieving. In these experiments, the quantum dots with a Rox dye attached to their surface were delivered by rapid mechanical deformation and observed over time. These data yielded an estimated minimum delivery efficiency of 35% and confirmed that the quantum dots delivered were in the cytosol and chemically accessible to the intracellular environment.
[00171] Transient pores are formed by rapid mechanical deformation of a cell as it passes through a microfluid constriction. The data supports this mechanism by demonstrating diffuse cytosolic staining (FIG. 26 at 2600), siRNA functionality (FIG. 29 at 2900) and the bidirectional movement of material across the porous membrane (FIG. 26 at 2920). Several parameters have been identified, such as constriction dimensions, number of constrictions in series and cell speed that affect the viability and efficiency of delivery (FIG. 25). These parameters can therefore be used to optimize the device design for individual applications based on the cell type and the size of the delivery material.
[00172] In example 2, this technique is based on micro-fluid systems, which can be incorporated into a larger integrated system consisting of multiple pre-treatment steps before delivery and post-treatment classification analysis steps. At an average throughput rate of 10,000 cells / second, the delivery device can, for example, be placed in line with a flow cytometry machine to classify cells or perform other analytical tasks immediately after delivery.
[00173] The devices, systems and methods described in this document provide several potential advantages over existing methods. Similar to electroporation and microinjection, it is a method based on the formation of pores and, therefore, does not have exogenous materials, chemical modification of payloads or endocytic trajectories. In contrast to electroporation, however, it does not have electric fields that have had limited success in delivering protein, can damage part of the payload or cause cytotoxicity. In fact, current results have demonstrated high relativity feasibility in most applications and sensitive payloads, such as quantum dots, appear to be undamaged. The present material thus provides significant advantages in areas such as the identification and screening of cytosolic material in which quantum dot damage due to electroporation can be a problem and the use of chemical delivery methods can restrict the range of surface chemicals - available.
[00174] Example 2 also demonstrated the device's ability to deliver proteins to the cell cytosol. Modeling data and estimates indicate that the present material could deliver 10 to 100x more material per cell compared to previous practices, such as the use of cell-penetrating peptides or electroporation. This improvement in delivery rates provides a potent method for use in protein-based cell reprogramming, for example, in which the delivery of transcription factors to cell cytosol is a major obstacle to the development of reliable iPSC generation methods. One can also use the present material to study a disease mechanism by delivering several proteins / peptides of interest. In fact, the present material can be used for screening high-performance peptide libraries due to the fact that, unlike most techniques based on nanoparticles or CPP, the present material is insensitive to the structure and chemistry of the protein, they do not have endocytotic trajectories and do not affect the functionality of the protein.
[00175] Due to the fact that the present matter has demonstrated the potential for delivery to primary cells, cytosolic delivery by rapid mechanical deformation can be implanted as an ex vivo treatment mechanism. In this approach, the patient's target cells, isolated from blood or other tissue, are treated by the device outside the patient's body and then reintroduced into the body. Such an approach takes advantage of the increased delivery efficacy of protein or nanoparticle therapies and is safer than existing techniques due to the fact that it obviates the need for potentially toxic vector particles and mitigates any potential side effects with reticuloendothelial cleaning and delivery outside. target.
[00176] In example 2, the silicon-based devices were manufactured in a microfabrication facility using photolithography and deep reactive ion notching techniques. In this process, silicon sheets 15.24 cm (6 inches) with a thickness of 450 pm are treated with Hexamethyldisilazane (HMDS), coated by spin with photosensitive resin (OCG934, FujiFilm) for 60 seconds at 3000 rpm, exposed to light UV (EV1- EVG) through a chrome mask with the constriction channel design and developed in AZ405 solution (AZ Electronic Materials) for 100 seconds. After 20 minutes of cooking at θO'C, the blade was notched by a deep notch with reactive ion (SPTS Technologies) at the desired depth (typically, in this example, 15 pm). Piranha treatments (H202 and H2S04) were used to remove any remaining photosensitive resin after the carving process was completed. To record the access holes (ie, entry and exit), the process was repeated on the opposite side of the blade (ie, the one that does not contain the notched channels) with the use of a different mask, which contains the orifice patterns and a thicker photosensitive resin AZ9260 (AZ Electronic Materials).
[00177] Oxygen plasma and RCA cleaning were used to remove any remaining impurities. Wet oxidation was used to produce 100 to 200 nm silicon oxide before the slide was anodically attached to a Pyrex slide and placed in individual devices. Each device individually inspected for defects before use.
[00178] Before each experiment, the devices were mounted on a retainer with inlet and outlet reservoirs, all custom-designed and produced by Firstcut. These reservoirs interface with the device using O Buna-N rings (McMaster-Carr) to provide proper sealing. The inlet reservoir is connected to a pressure regulator system using Teflon tubing to provide the driving force necessary to push material through the device.
[00179] Example 2 can accommodate pressures up to 0.48 MPa (70 psi). The cell culture of Example 2 included HeLa (ATCC), HeLa cells expressing GFP and DC2.4 (ATCC) that were grown in Dubelco's modified essential medium with high glucose content (DMEM, Mediatech) supplemented with 10% fetal bovine serum % (FBS) (Atlanta Biologies) and 1% Penicillin Streptomycin (Mediatech). Primary human fibroblast cells (NuFF) (Globalstem) were cultured in DMEM with high glucose content supplemented with 15% FBS. The cells were kept in an incubator at 37 ° and 5% CO2. When applicable, adherent cells were suspended by treatment with 0.05% Trypsin / EDCTA (Mediatech) for 5 to 10 minutes.
[00180] Mouse embryonic stem cells (mESC) were cultured in mouse embryonic fibroblasts (Chemicon) in a medium consisting of 85% silencing DMEM, 15% fetal bovine serum, 1 mM glutamine, beta mercaptoethanol at 0, 1 mM and 1% non-essential amino acids supplemented with 1,000 units / ml of LIF (Millipore, USA). The cells were cultured every 2 to 3 days using 0.25% Trypsin / EDTA. When treated with the device, mESCs were able to form colonies again and maintained normal morphology even 2 weeks after treatment.
[00181] To perform an experiment for example 2, the cells were first suspended in the desired delivery buffer (growth medium, phosphate buffered saline (PBS) or PBS supplemented with 3% FBS and 1% F-68 Pluronics (Sigma)), mixed with the desired delivery material and placed in the inlet reservoir of the device. This reservoir is connected to a compressed air line controlled by a regulator and the selected pressure (0 to 0.48 MPa (0 to 70 psi)) was used to drive the fluid through the device. The treated cells are then collected from the outlet reservoir. The cells were incubated at room temperature in the delivery solution for 5 to 20 minutes after treatment to ensure pore closure before being subjected to any further treatment.
[00182] In example 2, experiments that compare the delivery of dextrans of different sizes or protein vs. dextran, the molecules of interest were co-delivered, that is, they were used in the same experiment, with the same cell population, in the same device and differentiated based on their fluorescent identifications. All experimental conditions were performed in triplicate and the error bars represent two standard deviations.
[00183] To deliver dextran molecules identified by fluorescence (Invitrogen) or Apolioprotein E (Apolioprotein), the experiments in example 2 were conducted as described above so that the delivery buffer contained 0.1 to 0.3 mg / ml of dextran or 1 mg / ml Apolioprotein E, respectively.
[00184] To deliver fluorescein-conjugated BSA (Invitrogen), cells were first incubated in culture medium containing 5 mg / ml of unidentified BSA (Sigma) for 2 hours at 37 ° and then treated with the device of example 2 with the use of a delivery buffer containing 1 mg / ml of the fluorescein-conjugated BSA. The pre-incubation step aimed to minimize the non-specific binding of BSA identified with cell surface fluorescence.
[00185] GFP silencing for example 2 was measured as the percentage reduction in an average fluorescence intensity of the population compared to untreated controls. Lipofectamine 2000 + siRNA particles were prepared by combining 1 µg of siRNA with 1 µl of Lipofectamine 2000 reagent in 100 µl of PBS. After 20 minutes of incubation at room temperature, 20 µl of this mixture was added to each experimental well containing approximately 20,000 cells and 100 µl of medium. The cells were allowed to incubate with the particles for 18 hours before analysis.
[00186] In example 2, gold nanoparticles were prepared by conjugating 1000 MW of polyethylene glycol (PEG) finished in thiol on the surface of the nanoparticles, excess PEG was then washed four times by centrifugation (10,000 rcf for 30 minutes) and the resulting material suspended in PBS at a final concentration of 100 nM. To imagine the delivery of GNP to HeLa cells, the cells were suspended in PBS supplemented with 3% FBS, 1% F-68 Pluronics and 47 nM GNP; treated by a 10 pm-6 pmx5 device and fixed at 2.5% (w / v) glutaraldehyde, 3% (w / v) paraformaldehyde and 5.0% (w / v) sucrose in cacodulate buffer 0.1 M sodium (pH 7.4). After fixing overnight, cells were post-fixed in 1% (w / v) OsO4 in veronal-acetate buffer for 1 hour. They were stained in a bloc overnight with 0.5% uranyl acetate in veronal acetate buffer (pH 6.0), dehydrated and incorporated in Spurr resin. The sections were cut on a Reichert Ultracut E (Leica) at a thickness of 70 nm with a diamond knife. The sections were examined with an EM410 electron microscope (Phillips).
[00187] In example 2, a Neon electroporation system (Invitogen) was used to transfect NuFF cells with 70 kDa dextrans identified with fluorescein and 3 kDa identified with pacific blue. The manufacturer's procedure was followed in washing cells and suspending them in the appropriate buffers. The cells were treated using a 10 µl tip at a density of 10 cells / ml with a dextran concentration of 0.1 mg / ml. The three conditions used were as follows: 1) One 20 ms pulse of 1,700 V 2) Three 10 ms pulses of 1,600 V 3) Two 20 ms pulses of 1,400 V. Conditions 1 and 3 were both recommended by the manufacturer as ideal conditions for transfection of human fibroblast cells with 84% and 82% eGFP plasmid delivery efficiencies, respectively.
[00188] In the confocal images of example 2, the samples were centrifuged at 800 rcf for 4 minutes and washed 2 to 3 times with PBS before imaging. Confocal images were taken in live cells using the C1 confocal complement unit in a Nikon TE2000-U inverted microscope with a 60x water immersion lens. The fluorescence samples were excited by a 405 nm laser and detected using a standard DAPI filter (Nikon).
[00189] In the fluorescence microscope of example 2, the samples were centrifuged at 800 rcf for 4 minutes and washed 2 to 3 times with PBS before imaging. The images were obtained using an Axiovert 200 (Zeiss) inverted microscope equipped with Neofluar lenses (Zeiss). The fluorescence excitation was provided by an X-cite 120Q mercury lamp (Lumen Dynamics). The microscope is adjusted with a Hamamatsu C4742-95 camera (Hamamatsu) and the images were analyzed by Imaged (NIH).
[00190] In the flow cytometry of example 2, for cell analysis after a delivery experiment, the cells were washed 2 to 3 times with PBS (> 100 pl per well in a 96 well plate). These were then resuspended in PBS supplemented with 3% FBS, 1% F-68 Pluronics and 10 µg / ml of porpidium iodide (Sigma). The cells were analyzed in an LSR Fortessa (BD Biosciences) or FACSCanto (BD Biosciences) equipped with a high-performance sampling robot. The 405 nm and 488 nm lasers were used to excite the desired fluorophores. Proidium iodide (live / dead stain), fluorescein and Pacific blue signals were detected using 695 nm, 530/30 and 450/50 long-pass filters, respectively. Data analysis was conducted using FACS Diva (BD Biosciences) and FlowJo (FlowJo) software. Example 3 - Stem Cells and Immunological Cells
[00191] Proteins, nanoparticles, siRNA, DNA and carbon nanotubes have been successfully delivered to eleven different cell types, including embryonic stem cells and immune cells. In fact, the ability to deliver structurally diverse materials and their applicability to hinder the transfection of primary cells indicate that the device and methods have wide applicability in clinical and research applications.
[00192] In example 3, each device consists of 45 parallel and identical microfluidic channels, containing one or more constrictions, notched on a silicon chip and sealed by a Pyrex layer. The width and length of each constriction band (described in more detail below) from 4 to 8 upm and 10 to 40 pm respectively. The device of example 3 was typically operated at a throughput rate of 20,000 cells / s, yielding almost one million treated cells per device prior to failure, due to obstruction. The parallel channel design was chosen to increase throughput, while ensuring uniform treatment of cells, due to the fact that any obstruction or defect in a channel cannot affect the flow speed in the nearby channels (the device can be operated at constant pressure ). Before use, the device can first be connected to a steel interface that connects the inlet and outlet reservoirs to the silicon device. A mixture of cells and the desired delivery material can then be placed in the inlet reservoir and the Teflon tubing is attached to the inlet. A pressure regulator can then be used to adjust the pressure in the inlet reservoir and drive the cells through the device. The treated cells can be collected from the outlet reservoir.
[00193] The parameters that influence the delivery efficiency that have been identified (see, for example, example 2 above) can include cell speed, constriction dimensions and number of constrictions (thus changing the shear and compression rates suffered by). For example, the delivery efficiency of impermeable membrane, 3 kDa dextran molecules identified by pacific blue to living HeLa cells increases monotonically with cell velocity through different constriction designs (for example, FIG. 25 in 2500). Constriction dimensions also impact delivery; increasing the length of constriction from 20 pm to 40 pm almost doubled the delivery efficiency at all operating speeds (eg, FIG. 25 in 2500), with minimal effect on viability (eg, FIG. 25 in 2510). Decreasing the constriction width had a similar effect. Increasing the number of constraints in series also increased delivery efficiency so that a device with five constraints of 10 pm in length in series presented a unique design of 10 pm, 20 pm or 40 pm in length across all cell speeds (for example, FIG. 25 in 2500 and 2510). In these data, the 0 mm / s data points correspond to the control case so the cells go through the same treatment as the other samples, but are not passed through the device like this reflecting any endocytic or surface binding effects.
[00194] To investigate the versatility of the technique, its ability to deliver model dextran molecules to several cell types that are traditionally difficult to transfect has been evaluated, especially immune cells and stem cells. Dextrans of 70 kDa and 3 kDa identified by fluorescence were used for these experiments due to the fact that they are similar in size to many protein and siRNA molecules, respectively, easy to detect by flow cytometry and have minimal surface binding effects since are negatively charged.
[00195] FIG. 30 illustrates the applicability of the present matter for all cell types. In 3000 the delivery efficacy and viability of NuFF cells treated with a 30 pm-6 pm device to deliver 3 kDa and 70 kDa dextran is shown. In 3010 the delivery effectiveness and viability of murine dendritic cells isolated from the spleen treated with a 10 pm-4 pm device to deliver 3 kDa and 70 kDa dextran is shown. In 3020 the delivery efficacy and viability of murine embryonic stem cells treated with a 30 pm-6 pm device to deliver 3 kDa and 70 kDa dextran is shown. In 3030 the effectiveness of delivering 3 kDa dextran is shown and in 3040 70 kDa dextran is shown to B cells (CD19 +), T cells (TCR-B +) and Macrophages (CDI lb) isolated from mouse whole blood and treated by devices 30 pm-5 pm and 30 pm-5pmx5 at 1,000 mm / s. The 3 kDa and 70 kDa dextrans were identified with pacific blue and fluorescein respectively. All data points were performed in triplicate and the error bars represent two standard deviations.
[00196] Using various device designs, dextran molecules were delivered to newborn human foreskin (NuFF) fibroblasts (3000), primary murine dendritic cells (3010) and embryonic stem cells (3020). These experiments yielded minimal loss (<25%) in cell viability (3000, 3010 and 3020) and the results in murine embryonic stem cells indicate that the method does not induce differentiation. In further studies, white blood cells (white cell layer) were isolated from mouse blood by centrifugation and treated with the device. B cells, T cells and Macrophages, as differentiated by antibody staining, indicated successful delivery of both 3 kDa and 70 kDa dextrans (3030 and 3040).
[00197] In order to illustrate the potential of the present matter in dealing with current delivery obstacles, several experiments were conducted in possible applications in the range of cellular reprogramming for detection based on carbon nanotube. In addition to the specific application materials detailed below, the present material has demonstrated the successful delivery of a variety of test payloads such as Apolioprotein E, bovine serum albumin and GFP plasmid.
[00198] FIG. 31 illustrates input data for nanomaterial and antibody. 3100 shows the delivery efficacy and viability of HeLa cells treated with a 10 pm-6 pmx5 device to deliver 3 kDa dextran identified with Pacific blue and carbon nanotubes involved in DNA identified with Cy5. In 3110, overlapping bright field cells with Raman diffusion in the G band (red) are shown to indicate delivery of carbon nanotubes in treated cells (left) vs. endocytosis (right). Scale bars at 2 pm. At 3120 a fluorescent micrograph of a HeLa cell is shown 18 hours after delivery of 3 kDa dextran identified with pacific blue (middle panel) and tubulin antibodies with an Alexa Fluor 488 tag (right panel). Scale bars at 3 pm. 3130 shows the delivery efficacy and viability of HeLa cells treated with a 10 pm-6 pmx5 device, at 500 mm / s, for delivering anti-tubillin antibodies identified with Alexa Fluor 488. Delivery efficiency in antibody concentrations different is compared to an endocytosis control at 10 pg / ml and untreated cells.
[00199] The verification of successful delivery of carbon nanotubes (encapsulated by a DNA oligonucleotide) by flow cytometry (3100) and Raman spectroscopy (3110). Antibodies to tubulin were also delivered (3120 and 3130) using these techniques, yielding a diffuse distribution throughout the cell that could be consistent with cytosolic delivery. The materials mentioned above are currently difficult to deliver to cell cytosol and each material usually requires specialized modification to facilitate delivery. In example 3, all four materials were delivered to HeLa cells using the same set of conditions on a 10 pm-6 pmx5 device.
[00200] The effective delivery of proteins to primary cells can enable several therapeutic applications. An obstacle in cell reprogramming, for example, is the ineffectiveness of previous CPP-based protein delivery methods. FIG. 32 illustrates protein delivery applications. 3200 shows a western blot analysis of delivery of c-Myc, Klf-4, Oct-4 and Sox-2 by cell penetrating peptides versus a 10 pm-6pm device to NuFF cells. Each of the four proteins has 9 additional arginine groups (9R) to facilitate retention. The lysate (Ly) columns correspond to the protein content of the cells that are washed and lysed while the broth columns correspond to the protein content of the medium environment. 3210 shows the delivery efficacy and viability of murine dendritic cells isolated from the spleen treated with a 10 pm-4 pm device to deliver 3 kDa dextran identified with pacific blue and ovalbumin identified with Alexa Fluor 488. All data points were performed in triplicate and the error bars represent two standard deviations.
[00201] The ability to deliver four exemplary transcription factors (Oct4, Sox2, c-Myc and Klf-4) to human fibroblast cells was examined and compared to a CPP method (3200). The results show that in addition to not having endocytosis, which can leave a lot of material trapped in endosomes, delivery by rapid mechanical deformation produces significantly higher delivery efficacy for all 4 proteins. This result is in line with the simulation work mentioned earlier, which indicated that the present material may have a 10 to 100x improvement in protein delivery compared to CPPs.
[00202] The presentation of antigen in dendritic cells (DCs) is another area in which the present matter offers an advantage. The researchers have explored methods for expressing antigens at DC class MHC receptors in order to induce a potent cytotoxic T cell response. The present article, which has direct clinical implications in the preparation of a cancer vaccine, for example, relies on the cytosolic delivery of antigenic proteins, due to the fact that the presentation of MHC class I is almost exclusive for cytosolic proteins. By facilitating the direct cytosolic delivery of material, the present material serves as a platform to generate a cytotoxic T cell response in vivo against a specific antigen. To illustrate this ability, ovalbumin identified with Alexa 488, a model antigen protein, was successfully delivered to murine dendritic cells derived from the spleen (3210). Despite the higher rate of endocytosis in this cell type, the device produced a significant increase in delivery rates compared to endocytosis controls (0 mm / s). In addition, the material delivered is present in the cytoplasm due to the mechanism of cell deformation. This feature is particularly important for antigen delivery, due to the fact that cytoplasmic pressure is a critical requirement for presenting MHC class I antigen.
[00203] The system in example 3 is a research tool enabled to deliver carbon nanotubes, gold nanoparticles and antibodies (FIG. 31) - three materials that are difficult to deliver with current techniques. The present article significantly expands the ability to probe intracellular processes, facilitating the staining of antibody and the quantum dot of structures / proteins of living cells and enabling the use of carbon nanotubes as a cytosolic molecular probe or chemical sensor. As a robust protein delivery method, it can be used for high-throughput screening of peptide / protein libraries due to the fact that, unlike most techniques based on CPP or nanoparticles, this method is insensitive to chemistry and structure proteins, does not have endocytic trajectories and does not affect the functionality of the protein.
[00204] Additionally, the present matter is useful for therapy (FIG. 32). For example, a patient's target cells are isolated from blood or other tissue, treated by the device to deliver the desired therapy and reintroduced into the body. Such an approach capitalizes on increased delivery efficacy of therapeutic macromolecules and is safer than existing techniques due to the fact that it obviates the need for potentially toxic vector particles and mitigates any potential side effects with reticuloendothelial cleaning and off-target delivery. Example 4 - Personalized Cancer Vaccinations
[00205] Current obstacles in the intracellular delivery of macromolecules are a significant barrier to better understanding disease mechanisms and the implementation of new therapeutic approaches. Despite recent advances in delivery technology, treatment of patient-derived cells remains an obstacle and current methods often rely on toxic electrical fields or exogenous materials. The microfluidic platform and related systems and methods rely on the mechanical deformation of the cells to facilitate delivery. This controlled physical approach produces results in previously challenging areas, such as protein-based cell reprogramming and quantum dot delivery.
[00206] The most effective and direct way of influencing the behavior of a cell and delivering active agents to the cell's cytoplasm. The intracellular delivery of macromolecules thus plays a critical role in research and development (R&D), with applications in the range of drug development to the study of biochemical processes to therapeutic applications. Current methods, however, have limitations. They usually have low efficacy in patient-derived (primary) cells, have toxic electrical fields or exogenous material, and are poorly adapted to deliver structurally diverse materials, such as proteins.
[00207] A robust delivery platform capable of addressing these problems enables significant advances in biological research and serves as the basis for a new generation of therapies such as personalized cancer vaccination. An effective protein delivery method for immune cells, for example, can serve as a cancer vaccination platform.
[00208] As described above, the microfluidic devices, systems and related methods described in this document facilitate the intracellular delivery of material by rapidly deforming a cell as it passes through a constriction. The deformation process causes transient rupture of the cell membrane and thus allows passive diffusion of material from the surrounding buffer into the cell cytosol. Eliminating the need for exogenous materials and electrical fields that current methods rely on, this approach provides a robust and streamlined approach to delivery with reduced toxicity. Therefore, this method can serve as a broad platform for intracellular delivery of macromolecules with advantages in some research and clinical applications, such as cancer vaccination.
[00209] FIG. 34 is an illustration representing a system in which a patient's blood is treated by a micro-fluid device for the delivery of macromolecules. One embodiment of the present subject includes a system in which dendritic cells (DCs), isolated from a patient's blood, are treated by the device, ex vivo, to activate them against a particular cancer antigen and then reintroduced into the patient's bloodstream. . For example, the delivered antigen is a commonly expressed protein known to be associated with a particular disease or a specific patient obtained from a biopsy. By delivering cancer antigens directly to the cytoplasm DC, one can explore the trajectory of presenting MHC-I antigen and induce a potent cytotoxic T lymphocyte (CTL) response in the patient. These activated T cells then search for and destroy any cancer cells that express the target antigen. The flexibility of the platform in established use, disease-specific antigens or that derived directly from a patient's tumor allows to treat patients who are resistant to other therapies. In fact, it provides a targeted and personalized disease response with minimal side effects. This modality can be implemented in a typical hospital laboratory (<1 hour per treatment) with a trained technician. Due to its small size and relative simplicity, a patient-operated treatment system can also be used.
[00210] The cancer vaccine method has been demonstrated in a mouse model. The system was used for the successful delivery and processing of ovalbumin, a model antigen, to murine dendritic cells and, as indicated by increased antigen presentation, SIINFEKL peptide, in MHC class I receptors. These treated dendritic cells promote a lymphocyte response Proliferative cytotoxic T (CTL) in vitro. Treated DCs are reintroduced into the animal to generate a CTL response in vivo. The devices are useful for delivering antigens to DCs isolated from human blood.
[00211] The data indicates that the device is capable of delivering material to sensitive primary cells (including DCs) without causing excessive cell death. Thus, cell damage is not a serious problem. The immune response can be improved by increasing the number of treated cells, increasing the quantity and diversity of delivered antigen and / or co-delivery activation factors, such as lipopolysaccharide. Little or no toxicity was observed with cells treated with the device, thus making the methods not only possible, but advantageous for therapeutic veterinary and human applications. Example 5 - Treatment of Blood Cancer
[00212] As described in example 4, rapid mechanical deformation of cells can provide a robust means of delivering antigens to dendritic cells (DCs) and thus can be a platform for cell therapies. This system is based on the revelation that the rapid mechanical deformation of cells can cause the formation of transient pores in the membrane that enable the diffuse delivery of material from the surrounding environment. Unlike the existing therapies discussed earlier, this method does not have adapted fusion proteins, antigen cross presentation, viral vectors, nanoparticles or endocytosis mechanisms; therefore, it provides great improvements in in vivo efficacy while reducing therapeutic costs. The flexibility and simplicity of this fundamentally different approach enables a broad platform for dendritic cell activation that can induce a CD8 response against a variety of cancer antigens. The system can target cancers in the blood, such as B-cell lymphoma, which are more receptive to immune therapies, as well as several additional cancers (for example, melanoma, pancreatic cancer, etc.) and provides a new approach to personalized embroidery to fight the disease.
[00213] Cell therapy against cancer is an attractive option due to its ability to activate the patient's immune system and trigger a CD8 T cell response with specificity for long-lasting antigen against the disease. These therapies, like the recently approved Proven® for prostate cancer, have minimal side effects in relation to chemotherapy and radiation treatment. However, one of the biggest barriers to developing cell therapies has been to achieve appropriate antigen presentation by delivering antigens in the cell cytoplasm. Traditionally, the activation of a CD8 effector response differs from a CD4 response by the location where the foreign protein enters the antigen-presenting cell (for example, dendritic cell). The proteins found in the cytoplasm induce a CD8 response while the extracellular proteins captured by endocytosis induce a CD4 response. As the mechanism of cross-presentation within cells that present antigen remains elusive, a reliable method can be developed to deliver antigen directly to the cell cytoplasm for advanced therapies that utilize the potent cytotoxic CD8 response. An effective and robust method of cytoplasmic delivery to dendritic cells is used as a platform to induce immune responses against a variety of cancers.
[00214] The HeLa cell experiments, illustrated in FIG. 8A and FIG. 11, indicated that the rapid mechanical deformation of cells results in the formation of transient lesions / pores in the cell membrane, which allow passive diffusion of material from the surrounding buffer into the cell cytoplasm. This previously unreported phenomenon produces cells that are viable and normally proliferate after treatment. The experiments indicated that larger molecules exhibit lower delivery rates than smaller ones, thus indicating a diffuse mechanism. Successful siRNA delivery and diffuse cytosol staining, as measured by confocal microscopy, also indicate that the materials delivered are in the cytosol and in an active / accessible state. Traditionally, antigen delivery methods typically show potential in cell lines, but fail to translate into primary immune cells. The delivery method described in this document, however, is independent of endocytotic trajectories or cell response to exogenous materials, which can vary significantly by cell types and primarily has membrane bilayer properties. Therefore, due to its simplicity and innovative trajectory, this technology is more receptive to the transition from cell line to primary immune cell delivery and thus provides a further improvement in antigen presentation.
[00215] MHC class I antigen presentation and dendritic cell maturation can be analyzed by antibody staining in response to the delivery of ovalbumin protein. T cells harvested from transgenic OT-I and OT-II TCR mice can also be used to measure the proliferation of CD8 and CD4 in response to the loading of ovalbumin and / or SIINFEKL antigen. The system can be optimized for CD8 proliferation compared to dendritic cells initiated by endocytosis alone.
[00216] Primary murine dendritic cells are purified by separating MACS CD11lc + (Miltenyi Biotec, Alemana) from the spleens of B6 mice. A device containing constraints with a channel width of 6 pm capable of producing 13 pores in the HeLa cell membrane can be used. Due to the smaller size of these dendritic cells, microfabrication and testing devices with channel widths from 3 to 5 pm can be used for performance. The existing protocols for photo lithography and reactive ion deep groove can be modified to enable the effective manufacture of these devices. Dextran molecules identified by fluorescence can be used as model molecules to assess the effectiveness of FACS delivery. Subsequently, the ovalbumin protein can be delivered to the cells and evaluated by western blot transfer to confirm protein retention in the primary cells.
[00217] The maturation of dendritic cells can be examined by antibody staining CD80 and CD86 to show that the rapid deformation method induces cell maturation. The use of extracellular TLR agonists, such as lipopolysaccharide (LPS), can be considered if it is considered necessary to manually induce CD maturation after delivery. The protein ovalbumin can be delivered to dendritic cells and the antigen presentation can be quantified by MHC-T SIINFEKL antibodies. In addition, the effectiveness of antigen presentation in response to the delivery of specific TCR peptides can be evaluated to show the system's ability to deliver / present proteins vs. antigenic peptides. Subsequently, CD8 and CD4 T cells can be harvested from transgenic TCR OT-I and OT-II mice, respectively, spotted by CFSE and co-cultured with ovalbumin-treated dendritic cells for 5 days. The proliferation of T cells from both subsets can be measured by FACS. The design of the device can be optimized to produce increased levels of CD8 T cell populations compared to conventional in vitro methods (eg, endocytosis).
[00218] A versatile ability to induce CD8 responses with antigen specificity has been a goal of cancer cell therapies that have proven elusive so far due to inefficient antigen presentation or inadequate delivery method flexibility. The existing methods have several disadvantages including their dependence on harmful electric fields, the use of exogenous materials, modification of protein sequences and / or endocytotic trajectories to facilitate antigen delivery. The present matter, however, provides a fundamentally different approach to cytosolic delivery that is not overcome by any of the problems mentioned above. In addition, due to the nature of its pore-forming diffusion mechanism, this method is widely applicable for types of antigen and could thus treat a range of target cancers. The same mechanism can also be used to introduce additional signaling molecules to enhance DC mutation / activation to produce a more potent T cell response. Such a broad-based platform is more versatile and robust than any existing antigen delivery / presentation mechanisms under investigation for cancer vaccines.
[00219] Example 5 can have a broad impact. Given the country's immense social burden of cancer (estimated 570,000 deaths in the US in 2011); cancer is likely to afflict a significant proportion of the population. The afflicted population will benefit from the development of innovative cell therapies that empower the patient's immune system to fight the disease. The present article is a personalized and more effective treatment platform for a variety of types of cancer, such as cancers in the blood, for example, leukemias, lymphomas and multiple myelomas, as well as myeloproliferative neoplasms and myelodysplastic syndromes. The methods are also particularly useful for the treatment of metastatic cancers, for example, due to their propensity to spread through the bloodstream. Cancers with an unknown antigen epitope, for example, can be treated by digesting a tumor biopsy sample, delivering lysate to the patient's DCs in the body. This can enable activation of the host's T cells against a wide range of cancer antigens, thus ensuring effective treatment of multiple targets. This personalized aspect may be of particular interest to people who could develop rare forms of cancer, which are usually under-served by current treatments due to exposure in hostile environments. Adapting the treatment to the individual's disease, this method can provide timely effective care even in the most aggressive cases, such as cancers resistant to multiple drugs. This immune-based therapy can also be particularly effective in preventing metastasis (responsible for approximately 90% of cancer-related deaths) as CD8 T cells can easily locate and destroy metastatic cells while the immune memory provided through these treatments could prevent future relapse. In addition, as a research tool, this method can enable unprecedented mechanistic studies of antigen processing to better understand the antigen cross-presentation process and, therefore, improve the effectiveness of existing immunogenic activation methods. Active items. Example 6 - Cellular reprogramming
[00220] Stem cells play a critical role in current research in regenerative medicine, especially within the rapidly expanding field of tissue manipulation. iPSCs are of particular interest due to their capacity for self-renewal, demonstrated the ability to differentiate in any type of cell and autologous characteristics (specific per patient). Thus, iPSCs provide an opportunity to derive progenitor cells from multiple strains from a common pluripotent source, which can be combined in already distinct interactive tissue compartments. In addition, these cells could eventually obviate the need for human embryonic stem cells (hESCs) in clinical applications thus avoiding many of the moral and ethical debates induced by these cell types. In addition, patient-derived iPSCs prevent or minimize the problems of immune rejection of hESC-derived cells. Thus, current research is largely focused on developing effective virus-free protocols to produce large numbers of iPSCs.
[00221] iPSCs were originally generated by reprogramming adult murine and human fibroblasts (HFs) to a pluripotent state based on retroviral overexpression of the 4 transcription factors October 3/4, Sox2, c-Myc and Klf4. These iPSCs are not broadly identical to ES cells in global gene expression, DNA methylation and histone modification, but they are also capable of differentiating into cell types that represent all 3 germ layers. While iPSC technology has enormous potential for biomedical research and cell-based therapy, major obstacles must be overcome to realize its full potential. For example, most iPSC strains were derived from several somatic cells by retroviral or viral lenti introduction of genes encoding reprogramming factor, resulting in multiple chromosomal interruptions by viral vector integration, any of which can cause genetic dysfunction and / or tumor. In addition, reprogramming transgenes (particularly, c-Myc and Klf4) are closely associated with oncogenesis, which raises the possibility that their residual expression and / or reactivation may cause tumor formation. Thus, many laboratories have recently explored different non-integrating genome approaches, such as adenovirus, episomal vectors, mRNAs and microRNAs. Notably, it has been shown that iPSCs can be generated by direct delivery of the four reprogramming factors (Oct 3/4, Sox2, c-Myc and Klf4) fused to cell-penetrating peptides (CPP). Although it has been reported that the generation of mouse iPSCs can occur by delivering four factors fused by CPP to E.Coli, it can be shown that human iPSCs can be generated by four factors fused by CPP expressed in mammalian cells. However, both studies reported that the effectiveness of reprogramming protein-based reprogramming is very low (<0.01%). Since protein-based reprogramming does not involve any type of genetic material (DNA or RNA) and vector vehicle (virus or plasmid), direct protein delivery provides one of the safest reprogramming procedures. Protein-based human iPSCs have been shown to effectively generate functional dopamine neurons without abnormal properties associated with viral genome integration. As the effectiveness of protein-based reprogramming can be enhanced by the present matter with the use of delivery platform technology, the possibility of generating clinically viable iPS cells opens up widely. In addition, this approach allows for a finer level of control over cell function by evading stochastic processes that control translation and / or transcription in reprogramming of mRNA, plasmid and virus. The direct delivery of protein thus provides two fundamental advantages over alternative methods in that it avoids the risk of mutagenic insertion and allows more precise control of the highly sensitive reprogramming process. The delivery technology described in this document has demonstrated its ability to deliver high-efficacy proteins to HFs and stem cells. Experiments that compare the delivery capabilities of this technique to existing cell-penetrating peptide methodologies showed a significant increase in delivery using this approach (potentially 100x greater based on simulations). In addition, its physical pore formation mechanism eliminates the need for chemical modification or the use of exogenous compounds that are involved in alternative protein delivery methods. Small molecules, siRNA and other factors can also be co-delivered during reprogramming as the method is agnostic to the type of material that is delivered. This system, therefore, provides a unique tool to induce cellular reprogramming through direct protein delivery. This simple mechanism of action (that is, diffusion through pores) also makes it possible to predict and potentially control delivery quantities with high precision, thus facilitating optimization studies to improve the understanding of reprogramming dynamics and thus greatly increase efficacies. Finally, it can employ this microfluidic technique as a medical device to generate iPSCs for manipulating clinical tissue and cell therapy applications.
[00222] In addition, the applications of this system are not restricted to the delivery of protein. This technique can be included in a universal delivery method capable of delivering a range of macromolecules (DNA, RNA, proteins, sugars and peptides) to almost any cell type. This allows the host applications that are poorly served by current technologies. Current electroporation, nanoparticle and liposome-based methods, for example, usually have difficulty transfecting certain primary cells (such as immune cells or stem cells) and can be ineffective in delivering proteins and nanoproteins (such as quantum dots). Peptide delivery for disease mechanism applications and therapeutic screening can also be handled by this innovative method while contemporary practices usually require chemical modification or encapsulation. You can also use this method for nanoparticle-based detection applications to deliver modified quantum dots for organelle identification and mechanistic disease studies.
[00223] Intracellular delivery is a foundation for many applications of biological research in the range of fundamental studies of gene expression to disease mechanisms and, as discussed in this application, generation of iPSCs. Established delivery methods, such as liposomes, polymeric nanoparticles and electroporation, usually involve the use of exogenous compounds as a delivery vehicle (or electric fields in the case of electroporation) and are specific to material and / or cell. For example, lipofectamine (Invitrogen) can deliver DNA and RNA molecules (to subsets of cell lines or primary cells), but it cannot form the appropriate complex to deliver proteins or other macromolecules. Electroporation, on the other hand, while potential in its ability to target a variety of cell types, causes damage to the cell due to high electrical fields and has limited success in delivering protein. This makes it particularly unsuitable for the multiple transfections required in generating iPSC, for example. Membrane penetrating peptides are another delivery technique that is broadly specific for proteins. These peptide-based methods, however, have unpredictable effects on protein functionality and suffer from significant protein degradation in the dose. Therefore, the present article that describes a universal method capable of delivering a range of macromolecules (DNA, RNA, proteins, peptides, small molecules), with minimal cell death, enables unprecedented control over cell function on a unique technology platform , thus enabling studies of the mechanism of disease, identification of macromolecular therapeutic candidates, guided stem cell differentiation or reprogramming and the development of diagnostic techniques with reporter cell lines.
[00224] The microfluidic device described in this document can serve as a universal delivery platform with a broad base. As a microfluidic device, it enjoys the benefits of precise control under treatment conditions at a single cell level. The unique combination of single cell level control and macroscale productivity puts this device in a unique position compared to existing delivery methods. The data so far have demonstrated the system's ability to deliver material to about 11 different cell types including cancer cell lines, embryonic stem cells, primary fibroblasts and primary lymphocytes. Its mechanical mechanism also enabled the delivery of previously challenging materials such as carbon nanotubes and quantum dots.
[00225] Previous work with the use of recombinant proteins to produce iPSCs has shown prohibitively low efficiencies (<0.01%) and are therefore unsuitable for wide-spread clinical application. The device, systems and methods mentioned in this document, however, have demonstrated their ability to deliver proteins directly to the cytoplasm with high efficiency and minimal cell death, thus providing a convincing opportunity to produce substantial gains in reprogramming efficiency through more efficient delivery. effective. By directly determining the amount of protein available, you can exercise precise control over intracellular kinetics. Other reprogramming methods (eg, viral, mRNA and plasmid expression), on the other hand, have stochastic effects to determine the level of protein availability and are therefore unsuitable for kinetic studies. The low efficiency of current reprogramming methodologies indicates that the process is highly sensitive to stochastic variations and only a narrow range of levels of transcription factor expression will result in reprogramming. By delivering proteins directly to the cytoplasm, you can exercise unprecedented control over the availability of protein and, thus, more consistently impose the exact conditions necessary for reprogramming. These conditions, once identified and optimized, can be reproduced precisely for each cell being treated and thus dramatically improve the reprogramming efficiency.
[00226] This set of procedures enables / improves through a variety of intracellular delivery applications. In addition, the strictly mechanical nature of the set of procedures eliminates any potential complications that arise from the use of chemical agents or electrical fields. The data revealed no substantial change in cellular behavior as a result of treatment. Thus, this system is a high-efficiency universal intracellular delivery mechanism with particular utility in reprogramming applications.
[00227] Evidence indicates that the rapid deformation that occurs as a cell passes through constriction induces the formation of transient pores in the cell membrane, enabling the diffusion of macromolecules from the surrounding buffer in the cytosil. This set of procedures was demonstrated in 11 different cell types that include cancer cell lines, primary fibroblasts, primary lymphocytes and embryonic stem cells (without causing differentiation). A prototype has the capacity to treat approximately 20,000 cells / s and operates in a range of cell concentrations (104 to 108 cells / ml). Issues pertaining to obstruction have been largely mitigated by improving protocols and chip design so that each device has the capacity to treat approximately 1 million cells prior to obstruction, with the option of being cleaned and recycled. In addition, the multi-channel design provides significant redundancy so that obstructing one channel does not affect the performance of others. The pressure driven flow (at controlled constant pressure) and the parallel design of the channels ensure consistent flow per channel regardless of the percentage of channels blocked on the chip.
[00228] The device's ability to deliver dextran molecules to human fibroblasts and embryonic stem cells has been demonstrated. FIG. 35 illustrates the potential advantages of cell reprogramming. In 3500, the viability and efficiency of delivery of human embryonic stem cells treated with a 10 pm to 6 pm device deliver 3 kDa of dextran. In 3510, a western blot analysis of c-Myc, Klf-4, Oct-4 and Sox-2 delivery by cell-penetrating peptide versus a 10pm to 6pm cell device. The lysate columns (Ly) correspond to the protein content of cells that are washed and lysed while the soup columns correspond to the protein content of the media environment. In 3520, confocal microscopic images of NuFF cells fixed after delivery of the reprogramming factors. The proteins are labeled using an Alexa 488 conjugated anti-FLAG antibody and the nucleus is stained by DAPI.
[00229] Furthermore, the delivery efficiency of devices has been compared to that of a 9-arginine (CPP) method currently used for protein-based reprogramming. The results (3510) demonstrated a significant increase in the amount of c-Myc, Klf4, Oct4 and Sox2 delivered as measured by western blot. Confocal microscopy then confirmed the successful localization of these transcription factors to the cell nucleus (3520). A simple 2-D diffusion model was developed in COMSOL to simulate the delivery mechanism based on literature values for particle diffusivities inside and outside the cell cytoplasm. Fitting this model into the experimental data, it can be estimated that the set of procedures delivered 10 to 40% of the delivery material present in the buffer in the cell cytosil. In comparison, CPP methods for protein delivery are estimated to deliver only 0.1% of the buffer material to the cytosil. This approach thus provides a robust increase in the amount of reprogramming material delivered (10 to 100 times). Furthermore, it guarantees greater bioavailability of the delivered transcription factors.
[00230] FIG. 36 depicts the generation and characterization of human and mouse iPSC strains by direct delivery of fused reprogramming proteins. In 3600, initiate culture of mouse hepatocyte (first image); morphology after 6 cycle protein treatments (second image); established iPS colonies (third image); and staining of AP colonies of established iPS (fourth image). In 3610 immunological staining of ESC markers (Nanog, Oct4 and SSEA1) in p-miPSC. The nuclei were stained with DAPI (blue). In 3620, bisulfite sequencing analysis of the Oct4 promoter reveals almost complete epigenetic reprogramming in p-miPSC-1 and p-miPSC-2 strains. Open and closed circles indicate unmethylated and methylated CpG, respectively. In 3630, the potential for differentiation in vivo was analyzed by injecting p-miPSCs into mice with immunodeficiency and by staining with H&E teratomas. The resulting teratomas contained tissues that represent all three germ layers; ectoderm (neural tube or epidermis), mesoderm (cartilage or muscle) and endoderm (respiratory epithelium or intestine-like epithelium) cells. In 3640, chimeras derived from p-miPSC-1 (left panel) and p-miPSC-2 (right panel) in E13.5 fetuses show a high level of GFP from injected p-miPSCs. In 3650 to 3670, the human iPSC strains, p-hiPSC-01 (3660) and p-hiPSC-02 (3670), are generated by direct delivery of four reprogramming factors fused by CPP from adult human fibroblasts subjected to biopsy (3650).
[00231] FIG. 37 depicts preliminary protein reprogramming results. In 3700, a progression of morphological changes in fibroblasts in colonies. White arrows indicate potential reprogrammed cells. The red arrow points towards coalescent iPSCs that form a colony. In 3710 to 3760, the expression of the human embryonic stem cell marker Oct4, SSEA-4, Tra-60, Tra-80, alcline phosphatase (AP) in iPSC colonies. When appropriate, the small box represents a DA-Pl counter stain. Scale bars at 100 pm.
[00232] Since protein-based human iPSCs were generated and characterized, additional and completely reprogrammed human and mouse iPSCs were generated by the previous CPP-fused reprogramming factor delivery method, as examined by all criteria, including epigenetic analyzes, pluripotency in vivo and chimera formation (FIG. 36). However, despite the use of partially purified proteins, the reprogramming efficiency was still low (<0.1%) and took longer than viral reprogramming methods. Thus, an attempt was made to use the device to deliver 4 reprogramming proteins Oct4, Sox2, Klf4 and c-Myc to human fibroblasts in a buffer concentration of 80 pg / ml. The cells were treated 4 times with an interval of 48 hours between each delivery. After 14 to 20 days in culture, the first hiPSC-like colonies were reprogrammed. During that time, it was observed that the transition in fibroblast morphology as they formed iPSC colonies and they express various hESC markers (FIG. 37).
[00233] Clathrin, cavola and macropinocytosis are the three most commonly proposed mechanisms for endocytotic internalization. To examine whether endocytosis is evolved in macromolecular delivery following rapid cell deformation, it is possible to use known chemicals to block these mechanisms. Specifically, chlorpromazine can be used to inhibit clathrin-mediated endocytosis; genisteinna to inhibit cavit-mediated endocytosis; and 5- (N-ethyl-N-isopropyl) amirolide (EIPA) to inhibit macropinocytosis (all can be obtained from Sigma Aldrich). HeLa cells can be incubated with chlorpromazine (10 pg / ml), genistein (200 pM) and EIPA (25 pM) for 2 hours before treatment. Dextran, the dsRED and dsRED-9R proteins can then be delivered by rapidly deforming the treated cells. The respective delivery efficiencies, as measured by FACS, can illustrate the efficiency of inhibiting endocytosis in both device-based and CPP delivery mechanisms. Co-location experiments with endosome markers (Invitrogen) using confocal microscopy can also help to determine the percentage of material that is sequestered in endosomes.
[00234] It is possible to couple the rapid cell deformation system with other established methods of delivery, such as electroporation, to mitigate endocytotic mechanisms. Incorporating electrodes close to the constriction can couple deformation and electroporation to enable delivery effects to yield improved system performance over any of the individual methods. In addition, co-delivery of chemical agents such as Chloroquine (Sigma), various polymers or endosomal escape peptides can be used to assist endosomal escape of materials delivered in the rapid cell deformation system.
[00235] As a cell passes through constriction, it experiences a short but rapid shear and compaction (approximately 10 to 100 us). Tangential shear has previously been shown to induce pore formation. However, the system also induces mechanical compression. To assess these parameters, HeLa and HF cells can be incubated in 0.1 pg / ml Lantrunculin A (Invitrogen) for 1 hour before delivery to depolymerize the actin cytoskeleton. The fluorescently labeled dextran (Invitrogen) can then be delivered to the cell population treated using the rapid deformation device. These experiments can be repeated, too, with cells that were incubated in 10 µM Colchicine (Sigma) for 2 hours before delivery to depolymerize the microtubule network. FACS analysis can be used to measure delivery efficiencies of toxin-treated cells compared to untreated controls. Pore formation is believed to be color-related to the rate of deformation of a cell in response to a given geometry. The role of the cytoskeleton in resistance to deformation has been previously investigated using a device that probes the deformability of the cell to provide quantitative measurements of strain rates. In this method, the electrodes are placed on either side of a constriction and the change in capacitance between the two electrodes is measured as a cell passes through it. The changes in capacitance along the constriction are then correlated to the cell transit time, that is, its deformation rate. The delivery performance of the device, in the experiments mentioned above, can be correlated to these previous strain studies to produce a quantitative relationship between strain rate and pore efficiency.
[00236] Similar to published studies that characterize sonoporation, sets of scanning electron microscopy (SEM) and delivery electron microscopy (TEM) procedures can be used on samples fixed at defined time intervals after treatment to measure directly the size and distribution of the proposed pores over time. Cell fixation can be done at room temperature with the use of a 25% solution of Glutaraldehyde (Sigma). The cell samples can then be dehydrated by successive ethanol washes before imaging. Sets of Environmental SEM (ESEM) procedures can be used to image directly from fixed samples. Due to its relatively low resolution (approximately 200 nm), however, this set of procedures is suitable for detecting 1 to 0.5 pm of morphological changes in scale or lesions. If ESEM fails to detect any morphological change, the cells can be coated with a layer of 1 to 10 nm gold using a vacuum evaporator to improve the resolution to the nanometer scale needed to directly observe finer pore structures using SEM. TEM can also be used as a set of alternative imaging procedures if SEM fails to produce the desired results. These sets of procedures allow an individual to distinguish between a uniform pore mechanism and local delivery lesion and measure the distribution and average pore size. The pore size and distribution in cells that have undergone rapid cell deformation can be compared with untreated cells. A pore distribution located on the membrane surface indicates a lesion model while a more uniform distribution supports the uniform pore model.
[00237] The COMSOL software can be used to build a 3D model of the cell undergoing pore formation. The use of published data in cytoplasm and buffer diffusivities, combined with the appropriate pore models from mechanics studies, is possible to produce a predictive delivery model. The model emulates a porous membrane that separates a cytoplasm of low diffusivity from a region of buffer of diffusivity ala. According to the model's assumptions, the pores have a fixed size for a fixed amount of time before instant curing. Dynamic pore behavior, such as changes in shape and diameter, can be incorporated into complex models through coupling with MatLab or other software. Simulated delivery quantity predictions can be verified using experimental data based on FACS and gel electrophoresis (eg, western blots). These comparisons can be used to adjust the model and, therefore, enable it to predict the quantity of material delivered. The predictive capabilities of this model can simulate the effects of pore opening time, buffer concentrations and varying pore size and can therefore be used as a guide for future studies.
[00238] Multi-physics simulations (for example, COMSOL or CFD-ACE) can also be used to model the fluid flow throughout the device. These models can be used to more accurately predict flow velocities and shear stresses in the entry, exit and constriction regions. These data can be used to elucidate connections between flow velocity and shear stress in constriction projects. In addition, by building a broad model of the device, it is possible to study the consistency of pressure drops between different channels and adjust the inlet and outlet designs to ensure that all channels operate under almost identical conditions in order to improve the uniformity of treatment throughout the cell population.
[00239] The delivery phenomenon can be optimized primarily to increase delivery efficiency and cell viability. Population uniformity (that is, delivering a similar amount of material to each cell) can be used as a secondary optimization parameter. The initial results identified cell speed, constriction length, constriction width and shape of the input region as sensitive parameters. The composition of the media, on the other hand, does not seem to be a major factor. It is possible to build a series of devices, which systematically varies in width and constriction between 5 to 50 pm and 48 pm, respectively. Different taper angles as the channel narrows to form the constriction are possible. The efficiency and feasibility data for these devices, as measured by FACS, can be correlated to the modeling data mentioned earlier to better understand the effects of shear stress and constriction dimensions. This process can be repeated for different cell lines, which may respond differently to treatment. This data can be used to develop devices with optimized geometries and operating parameters for specific types (or specific subsets) of cells.
[00240] FIG. 38 depicts micrographs that illustrate alternative device structures. Brightfield micrograph of preliminary work combining constriction and electrodes (scale bar 30 pm). As illustrated in FIG. 38, the device can be modified by coupling the phenomenon of rapid deformation with electroporation. Gold electrodes can be incorporated on either side of the constriction by photo lithographic standardization and Au deposition to introduce a localized electric field into the channel. Subsequent experiments can identify operating parameter values (operating speed, frequency and electric field strength) that demonstrate improved performance over current methods. By coupling two independent pore mechanisms, you can exercise better control over the system and manipulate multiple parameters to optimize the system's performance for each cell type. In addition, electric fields can be used as a driving force to deliver larger charged molecules, such as DNA, that suffer from low diffusion rates.
[00241] A disposable and simplified version of the system, suitable for use by employees, is possible. Injection molding or hot engraving of PMMA and polycarbonate can be used to deploy a polymer-based version of the device. The subsequent reduction in costs would allow these devices to be used as a disposable tool, thus improving sterility and ease of use. In addition, by simplifying the pipe connections, mounting system and pressure regulator adjustments, it is feasible to supply an easy-to-use system.
[00242] Reprogramming based on fibroblast protein in iPS cells and studies of optimization of the reprogramming parameter space is possible. Previous studies have shown that iPSCs can be generated by direct delivery of reprogramming factors fused by CPP from both human and mouse tissues (FIG. 36) and that these protein iPSCs can differentiate into functional cells (eg, dopamine neurons) without abnormal phenotypes associated with viral iPSCs. However, due to many factors, including protein degradation in culture, delivery inefficiencies and degradation within cell endorsements, the reprogramming efficiencies for direct protein delivery are very low (<0.01%) for any practical use. The microfluidic devices described in this document can significantly increase the efficiency of protein-based reprogramming by allowing protein delivery to the cytoplasm, thereby avoiding harsh endosomal environment and the complicated endosomal process usually found in free protein delivery methods or encapsulated.
[00243] The generation of human iPSCs is facilitated by delivery on a microfluidic basis. The device is used to deliver one or more, for example, 4 reprogramming proteins (c-Myc (protein, Genbank Access Number NP_002458.2; DNA, Genbank Access Number NMJD02467.4), Klf4 (protein , Genbank Accession Number AAH30811.1; DNA, Genbank Accession Number NMJD04235.4), Oct4 (protein, Genbank Accession Number ADW77326.1; DNA, Genbank Accession Number HQ122675.1), and Sox2 ( protein, Genbank Accession Number NP_003097.1; DNA, Genbank Accession Number NM_003106.3);) for human embryonic fibroblasts (HFs). In addition to factor four Yamanaka (where MKOS is c-Myc-Klf4-Oct4-Sox2), several addition factors (for example, Lin28 (protein, Genbank Access Number AAH28566.1; DNA, Genbank Access Number NM_024674 .4) and Nanog (protein, Genbank Accession Number AAP49529.1; DNA, Genbank Accession Number NMJD24865.2), Esrrb (protein, Genbank Accession Number AAI31518.1; DNA, Accession Number on Genbank NMJD04452.3), Glisl (protein, Genbank Accession Number NP_671726.2; DNA, Genbank Accession Number NM_147193.2), and PRDM14 (protein, Genbank Accession Number NP_078780.1; DNA, Accession Number Genbank NMJD24504.3)) have been identified to improve reprogramming efficiency. It was completely established that the purification and mammalian expression of 6 factors (MKOS + Lin28 and Nanog; MKOSLN) and established the bioactivity of each factor using reporter assays. These factors can be expressed either in E.coli or in mammalian cells. Since proteins expressed in E.coli have no post-translational modifications such as phosphorylation, acetylation and ubiquitination, purified proteins can be used following expression in mammalian cells (HEK293 and CHO). The proteins expressed in E.coli (commercially available from Stemgent, Cambridge, MA) can be used for comparison. First, FLAG-tagged reprogramming factors expressed in HEK293 cells by transfection can be resuspended in an NP40 cell lysis buffer containing 50 mM Tris-HCI, pH 7.4, 250 mM NaCI, 5 mM EDTA, 1% of NP-40 and protease inhibitors. Following centrifugation, the collated soluble fraction can be added with balanced anti-FLAG M2 agarose affinity gel. After washing with PBS twice, retained proteins labeled with FLAG can be eluted by adding 0.1 mg / ml of FLAG peptide (Sigma). The human fibroblast suspension solution and 4 or 6 purified proteins can be applied to the device and the treated cells can be transferred to plates coated with 0.1% gelatin with hESC media conditioned for 1, 2, or 3 days before the next delivery cycle. After repeating protein delivery cycles (6 to 16) with the microfluidic device, the treated cells will be transferred to a mouse fibroblast (MEF) plate treated with mitomycin and cultured for 3 to 4 weeks with normal hESC media. IPSC colonies can become visible in 3 weeks after sowing in the MEF. The efficiency of iPSC generation can be compared with that of protein delivery using our recombinant proteins fused by CPP. These iPSC candidates can be thoroughly examined for all authentic iPSC criteria, including molecular and cellular properties as well as in vivo pluripotency, as described above. The use of 4 or 6 factors will generate iPSC strains with much improved efficiency. It is also possible to additionally express additional factors such as Esrrb, Glisl and PRDM14 and use these factors in reprogramming experiments.
[00244] MicroRNAs and / or mRNAs and reprogramming proteins and can be delivered in combination. The microfluidic device can be used to deliver not only proteins, but any other macromolecule. To take advantage of this unique property for non-optimal genome integration reprogramming, it is possible to combine the use of mRNAs and / or microRNAs and reprogramming factors. In particular, it is of great interest that iPSC strains can be successfully generated using only microRNAs. In fact, lipofetamine-based transfection of microRNAs can generate iPSC-like colonies. Since microRNAs are likely to induce reprogramming in a mechanism other than reprogramming factors, the appropriate combination of both reprogramming proteins and microRNAs via the microfluidic device can further improve reprogramming efficiency. The combined delivery of proteins and mRNAs can significantly facilitate reprogramming efficiencies. Thus, an ideal combined treatment of proteins, mRNAs and / or microRNAs can be delivered using the microfluidic device. Although microRNA / mRNA may not offer the equivalent level of control as proteins, the device capability for high productivity optimization studies still provides significant gains over previous approaches.
[00245] The unique features of the microfluidic device can allow the delivery of several quantified quantities of each factor, in a controlled and repeatable manner. The optimization of the current subject facilitates the development of a high-efficiency and reliable tool for delivering protein to HFs. It is possible to clarify the ideal frequencies and delivery quantities for each reprogramming factor. Unlike mRNA, plasmid and virus methods, the system lacks the stochastic nature of gene translation and / or expression to determine the effective intracellular concentration of transcription factors. Thus, the device's ability to deliver protein directly to the cytosil puts it in a unique position to exercise precise control over the intracellular environment. A number of delivery schedules are possible that vary the frequency of treatment (once every 1, 2, or 3 days) and protein concentration for each of the four factors independently. In particular, based on several reports that indicate that higher levels of Oct4 are critical for efficient reprogramming, it is possible to test the effect of different concentrations of Oct4 while maintaining the concentrations of other factors the same. Different concentrations of c- Myc can be evaluated for a given cell type due to the fact that its high levels have been shown to generate largely transformed colonies instead of iPSCs in some situations. In addition, it is possible to test the most frequent treatment effect of c-Myc due to its extremely short half-life (approximately 30 minutes).
[00246] The optimization of temporary treatment of reprogramming factors is facilitated with the use of the described methods. Each factor has a functional role and participates in the reprogramming process. At least one and, in some cases, combinations of factors are required to achieve the desired reprogramming result. For example, c-Myc is known to suppress the expression of differentiation genes. In addition, Klf4 is known to suppress the let-7 microRNA, which is related to differentiation and pluripotency inhibition pathways. Thus, temporarily regulated reprogramming may be possible with c-Myc and / or Klf4 for the initial period, based on a sub-ideal condition. In addition, although Nanog is not necessary for iPSC generation, it is known that it is crucial for the final establishment and maintenance of pluripotency. Thus, the effect of adding Nanog in the later stage of the reprogramming process can be tested. In addition, the sequential treatment of microRNAs and proteins can be tested and the reprogramming efficiency can be compared with those for each treatment or simultaneous treatment. This temporarily regulated reprogramming is feasible due to a unique feature of the microfluidic device and it may be important to further optimize protein reprogramming. The reprogramming efficiency can be calculated by dividing the number of colonies on day 28 by the number of HF cells treated. Once completed, regression analysis can be used to deduce the relative importance of each reprogramming factor, its ideal concentration, optimal frequency / timing of delivery and, as a result, the ideal protocol for generating iPSCs. The ability to control the amount and timing of protein delivered to each cell can help to understand the functional significance of each factor in the reprogramming process, thereby further improving the understanding of the cellular reprogramming process and the establishment of pluripotency. In addition, the results of this work can be used to further improve the design of the device to meet specific reprogramming demands and allow the eventual development of clinically applicable versions.
[00247] With the use of the optimized protein reprogramming procedure as described above, the protocol can generally be applied to adult human fibroblast cells specific to patient cells. Since the efficient differentiation of ESCs and iPSCs into functional dopamine neurons and the effects of transplantation have been studied, it is possible to generate strains of iPSCs or iPSC from human fibroblasts derived from Parkinson's patients. Once iPSC strains are generated and characterized, they are induced to differentiate into dopamine neurons and characterize their cellular, molecular, physiological and electro-physiological properties. Dopamine neurons are tested for in vivo functionality followed by transplantation in animal models of Parkinson's disease such as the genetic PD model, aphakia mice.
[00248] Microfluidic based protein delivery can be used for direct cell conversion, for example, the direct conversion of fibroblasts into other cell types such as neurons, hepatocytes and functional blood cells. In the past, manipulations used viral expression of key transcription factors, causing significant chromosome disruptions and gene mutations, thus highlighting the need to develop conversion methods that integrate genomes and non-viruses as direct protein delivery using the methods described above. Thus, the device can be used to deliver microfluidic based protein for direct cell conversion. Since the mammalian expression of certain transcription factors is sometimes challenging, it may be more feasible to test the conversion for one or two protein factors. However, it is possible to convert fibroblasts into another cellular target using a single factor, for example, Oct4 or Sox2 to generate blood or neural precursors, respectively. These proteins are readily available in a purified form, for cellular conversions using microfluidic based protein delivery.
[00249] FIG. 44 is a bar graph illustrating GFP silencing in HESCs as measured by GFP intensity 48 hours after treatment with active siRNA sequences and controls coded using the microfluidic device and related methods. FIGS. 45A and 45B are two diagrams that illustrate dye intensity and viability of human embryonic stem cells after delivery of 3kDa of blue dye.
[00250] Other modalities are within the scope and spirit of the invention. For example, due to the nature of software, the functions described above can be implemented using software, hardware, firmware, wiring or combinations thereof. Features that deploy functions can also be located physically in various positions, including being distributed so that portions of functions are deployed in different physical locations.
[00251] It should be noted that one or more references are incorporated in this document. To the extent that any material incorporated is inconsistent with the present disclosure, the present disclosure must control. In addition, to the necessary point, the material incorporated as a reference in this document must be disregarded if necessary to preserve the validity of the claims.
[00252] Additionally, although the description above refers to the invention, the description can include more than one invention.

权利要求:
Claims (29)
[0001]
1. Microfluid system to cause disturbances in a cell membrane for intracellular release of a payload, characterized by the fact that it comprises: a microfluid channel (10) that defines a lumen allowing a cell (20) suspended in a buffer ( 25) cross it, where the microfluidic channel (10) includes a cell-deforming constriction (15) causing disturbances, where a diameter of the constriction is 20 to 99% of the cell diameter (20), and where the constriction diameter (15) induces disturbances of the cell membrane large enough for a payload to cross.
[0002]
2. Microfluid system, according to claim 1, characterized by the fact that the diameter of the constriction (15) is 20% to 60% of the cell diameter (20).
[0003]
Microfluid system according to claim 1 or 2, characterized in that the constriction includes an inlet portion (35), a central point (40) and an outlet portion (45), optionally, in which the inlet portion (35) defines a constriction angle of 90 degrees.
[0004]
Microfluid system according to any one of claims 1 to 3, characterized in that it additionally comprises a plurality of microfluid channels (10) arranged either in series or in parallel.
[0005]
Microfluid system according to any one of claims 1 to 4, characterized by the fact that it additionally comprises a cell actuator, optionally, in which the cell actuator is selected from a group consisting of: a pressure pump , a gas cylinder, a compressor, a vacuum pump, a syringe, a syringe pump, a peristaltic pump, a manual syringe, a pipette, a piston, a capillary actuator, a human heart, human muscle and gravity.
[0006]
6. Method for delivering a payload in a cell, characterized by the fact that it comprises: providing the cell in a suspension solution; traverse a solution through a microfluidic channel that includes a cell deforming constriction, where the constriction diameter is 20-99% of the cell diameter, where, as the cell passes through the constriction, a deformation force is applied to the cell , causing cell disturbances large enough to cause a payload to cross it; and incubating the cell in a solution containing payload for a predetermined period of time after it has passed through the constriction.
[0007]
Method according to claim 7, characterized in that the suspension solution comprises a cell and the payload before, during and / or after going through the constriction.
[0008]
Method according to claim 6 or 7, characterized in that the diameter of the constriction is 20% to 60% of the cell diameter.
[0009]
Microfluid system according to any one of claims 1 to 5 or method as defined in claim 6 to 8, characterized in that a cross section of the microfluid channel (10) is selected from the group consisting of circular, elliptical , an elongated, square, hexagonal and triangular crack.
[0010]
Method according to any one of claims 6 to 9, characterized in that traversing the solution includes traversing the solution through an inlet portion, a central point and an outlet portion of the constriction, in which the inlet portion defines the constriction angle.
[0011]
11. Method according to claim 12, characterized in that the inlet portion defines a constriction angle at 90 degrees.
[0012]
Method according to any one of claims 6 to 11, characterized in that traversing the solution includes traversing the solution through a plurality of microfluid channels arranged either in series and / or in parallel.
[0013]
13. Method according to any of claims 6 to 12, characterized by the fact that incubating the cell in the solution containing the payload includes incubating the cell for 0.0001 seconds at 60 minutes.
[0014]
14. Method according to any one of claims 6 to 13, characterized by the fact that the deformation force is one of compression, or shear and compaction.
[0015]
15. Method for delivering a compound to a cell, characterized by the fact that it comprises: providing a cell in a suspended solution; passing the solution through a cell deformation constriction, where the diameter of the constriction is 20-99% of the cell diameter, such that the deformation force is applied to the cell as it passes through the constriction, thus causing disturbances in the membrane of the cell large enough for the payload to cross; and incubating the cell in the solution with a payload after the cell has been deformed.
[0016]
16. Method according to claim 15, characterized in that the suspension solution comprises a cell and the payload before, during and / or after going through the constriction.
[0017]
17. Method according to claim 15 or 16, characterized by the fact that the diameter of the constriction is 20% to 60% of the cell diameter.
[0018]
Method according to any one of claims 15 to 17, characterized in that the passage of the solution includes the passage of the solution through a plurality of constrictions positioned in series and / or in parallel.
[0019]
19. Method according to any one of claims 15 to 18, characterized in that the deformation of the cell includes deformation of the cell by 1 ps to 1 ms and / or in which the incubation occurs for 0.0001 seconds to 20 minutes .
[0020]
20. Method according to any one of claims 15 to 119, characterized by the fact that the deformation force is one of compression, or shear and compaction.
[0021]
21. Method for delivering a compound to a cell, characterized by the fact that it comprises: providing a suspension of a cell and a payload; flow the suspension through a cell deformation constriction, and that the diameter of the constriction is 20-99% of the cell diameter, to suddenly and temporarily deform the cell; and incubating the cell in the suspension for a predetermined period of time after the sudden and temporary deformation.
[0022]
22. Method according to claim 19, characterized by the fact that the constriction is in a microfluidic channel.
[0023]
23. Method according to claim 21 or 22, characterized by the fact that the diameter of the constriction is 20% to 60% of the cell diameter.
[0024]
24. Method according to any of claims 21 to 23, characterized in that the flow of the suspension through constriction in the microfluidic channel includes deforming the cell by 1 ps to 1 ms.
[0025]
25. Microfluid system for use with a cell (20) suspended in a solution (25) and to cause disturbances in a cell membrane, characterized by the fact that it comprises: a cell deformation constriction (15), in which the constriction diameter (15) is 20 to 99% of the cell diameter (20) to suddenly and temporarily deform the cell (20), where the constrictions (15) cause disturbances in the cell membrane (20), where the disturbances are large enough for a payload to cross.
[0026]
26. Microfluid system, according to claim 25, characterized by the fact that the constriction (15) is 20% to 60% of the cell diameter.
[0027]
27. Microfluid system, according to claim 25 or 26, characterized by the fact that the system is configured to cause sudden and temporary deformation to the cell (20) with the use of: (i) a microfluid channel (10) ; (ii) a plurality of micropillaries (100), optionally, in which the micropillaries (100) are configured in an arrangement; (iii) one or more movable plates (105); or (iv) bulky materials (110).
[0028]
28. Microfluid system according to any one of claims 25 to 27, characterized in that the cell is deformed by 1 ps to 1 ms.
[0029]
29. Methods according to claims 6 to 24, characterized by the fact that the method is used to release: (i) DNA, RNA, siRNA or protein for primary fibroblasts and stem cells for cell reprogramming; (ii) antigen, labeled macromolecules, peptides or RNA for primary immune cells or (iii) at least one of quantum dots, fluorescent components and carbon nanotubes to the target cell to assist in imaging the target cell or (iv) drugs for the target cell and the target cell is a tumor cell.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112014009346B1|2020-09-15|INTRACELLULAR DELIVERY

---

US10364441B2|2019-07-30|Methods tip assemblies and kits for introducing material into cells

---

Dong et al.2020|On-chip multiplexed single-cell patterning and controllable intracellular delivery

---

Hur et al.2020|Microfluidic cell stretching for highly effective gene delivery into hard-to-transfect primary cells

---

Tay2020|The benefits of going small: nanostructures for mammalian cell transfection

---

Kaladharan et al.2021|Microfluidic based physical approaches towards single-cell intracellular delivery and analysis

---

Tang et al.2021|Ultrahigh Efficiency and Minimalist Intracellular Delivery of Macromolecules Mediated by Latent-Photothermal Surfaces

---

US20210032589A1|2021-02-04|Methods and devices for the isolation of subcellular components

---

CN108148874B|2020-07-03|Application of degradable two-dimensional black phosphorus as gene editing vector

---

Sharei et al.2016|Intracellular Delivery of Biomolecules by Mechanical Deformation

---

Sharei2013|Cell squeezing: a vector-free microfluidic platform for intracellular delivery of macromolecules

---

WO2014102539A1|2014-07-03|Delivery method using mesoporous silica nanoparticles

---

Wu et al.2022|Controllable Fabrication of Small-Size Holding Pipets for the Nondestructive Manipulation of Suspended Living Single Cells

---

Yamoah et al.2021|Using magnetic nanoparticles in iPSCs

---

홍주희2016|Non-invasive Deactivation and Spatial Control of Intracellular Chromosome with Magnetic Nanoparticle

---

Zhao2014|Micro/Nanofluidics Based Electroporation for Precise Material Delivery to Cells

---

Beckwith2011|A Study of Cultured Cells on a Nanowire-based Reverse Transfection Device

同族专利:

---

公开号 | 公开日

---

DK2768942T3|2020-01-27|

---

CN103987836B|2018-04-10|

---

US20200277566A1|2020-09-03|

---

AU2012326203A2|2014-05-22|

---

CN107058101B|2021-06-01|

---

ES2764105T3|2020-06-02|

---

KR20140116374A|2014-10-02|

---

HUE047507T2|2020-04-28|

---

JP2014533936A|2014-12-18|

---

HRP20200051T1|2020-03-20|

---

JP2018023395A|2018-02-15|

---

EP2768942A1|2014-08-27|

---

CN103987836A|2014-08-13|

---

BR112014009346A2|2017-04-18|

---

PT2768942T|2020-01-21|

---

CA2852672A1|2013-04-25|

---

EP2768942A4|2015-05-27|

---

JP6219832B2|2017-10-25|

---

CA2852672C|2021-07-20|

---

KR102058568B1|2020-01-22|

---

AU2012326203A1|2014-05-15|

---

AU2012326203B2|2017-11-30|

---

LT2768942T|2020-04-10|

---

CN113337402A|2021-09-03|

---

RS59898B1|2020-03-31|

---

RU2656156C2|2018-05-31|

---

JP6629272B2|2020-01-15|

---

PL2768942T3|2020-05-18|

---

CN107058101A|2017-08-18|

---

EP2768942B1|2019-12-04|

---

RU2014119926A|2015-11-27|

---

EP3608394A1|2020-02-12|

---

US20190093073A1|2019-03-28|

---

SI2768942T1|2020-03-31|

---

US20140287509A1|2014-09-25|

---

US10696944B2|2020-06-30|

---

WO2013059343A1|2013-04-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE2502621C3|1975-01-23|1978-09-14|Kernforschungsanlage Juelich Gmbh, 5170 Juelich|Measurement of elastic and dielectric properties of the membrane of living cells|

---

US4478824A|1983-08-08|1984-10-23|Franco Robert S|Method for altering red blood cell function and survival|

---

FR2569477B1|1984-08-24|1987-01-02|Descartes Universite Rene|APPARATUS AND METHOD FOR DETERMINING THE DEFORMABILITY OF RED BLOOD CELLS|

---

JP2720161B2|1988-02-01|1998-02-25|株式会社アドバンス|Cell deformability measuring device|

---

JP2685544B2|1988-11-11|1997-12-03|株式会社日立製作所|Blood filter, blood test method, and blood test apparatus|

---

JP2532707B2|1990-03-08|1996-09-11|佑二 菊池|Blood circuit, blood measuring apparatus and blood measuring method using the same|

---

CA2080477A1|1990-04-24|1991-10-25|Flustat Pty. Ltd.|Oral vaccine comprising antigen surface-associated with red blood cells|

---

US5658892A|1993-01-15|1997-08-19|The General Hospital Corporation|Compound delivery using high-pressure impulse transients|

---

US6218166B1|1994-12-09|2001-04-17|John Wayne Cancer Institute|Adjuvant incorporation into antigen carrying cells: compositions and methods|

---

JP3926842B2|1995-03-08|2007-06-06|ザ・スクリプス・リサーチ・インステイチユート|ANTIGEN PRESENTATION SYSTEM AND T-CELL ACTIVATION METHOD|

---

US6051409A|1995-09-25|2000-04-18|Novartis Finance Corporation|Method for achieving integration of exogenous DNA delivered by non-biological means to plant cells|

---

AT234622T|1995-12-04|2003-04-15|Puget Sound Blood Ct|Preparations containing non-immunogenic platelets and red blood cells|

---

AU734196B2|1996-03-28|2001-06-07|Whitehead Institute|Opsonin-enhanced cells, and methods of modulating an immune response to an antigen|

---

US5885470A|1997-04-14|1999-03-23|Caliper Technologies Corporation|Controlled fluid transport in microfabricated polymeric substrates|

---

EP0882448B1|1997-05-05|2005-01-12|DIDECO S.r.l.|Method of encapsulating biologically active agents within erythrocytes and apparatus therefor|

---

US5842787A|1997-10-09|1998-12-01|Caliper Technologies Corporation|Microfluidic systems incorporating varied channel dimensions|

---

SE9704076D0|1997-11-06|1997-11-06|Holdingbolaget Vid Goeteborgs|Method for permeabilization of cell structures and use thereof|

---

GB9816583D0|1998-07-31|1998-09-30|Univ Ulster|Nucleic acid carrier|

---

US6562616B1|1999-06-21|2003-05-13|The General Hospital Corporation|Methods and devices for cell culturing and organ assist systems|

---

JP2002325572A|2000-12-25|2002-11-12|Univ Osaka|Method for introducing exogenous substance|

---

AU2002252073A1|2001-02-22|2002-09-12|The Scepens Eye Research Institute, Inc.|Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions|

---

WO2003020039A1|2001-08-28|2003-03-13|Rush-Presbyterian-St. Luke's Medical Center|Immune tolerance to predetermined antigens|

---

CA2468511A1|2001-11-27|2003-06-05|Kerstin Nolkrantz|A method for combined sequential agent delivery and electroporation for cell structures and use thereof|

---

US20030133922A1|2002-01-15|2003-07-17|Kasha John R.|Oral tolerance using allogeneic platelets in ITP|

---

US7501278B2|2002-06-05|2009-03-10|Panasonic Corporation|Extracellular potential measuring device and method for fabricating the same|

---

GB0214528D0|2002-06-24|2002-08-07|Univ Aberdeen|Materials and methods for induction of immune tolerance|

---

WO2004063342A2|2003-01-09|2004-07-29|Invitrogen Corporation|Cellular delivery and activation polypeptide-nucleic acid complexes|

---

US20060134067A1|2003-02-18|2006-06-22|Maxcyte, Inc.|Loading of cells with antigens by electroporation|

---

KR101223366B1|2004-05-03|2013-01-16|헤르메스 바이오사이언스, 인코포레이티드|Liposomes useful for drug delivery|

---

WO2005123905A1|2004-06-17|2005-12-29|Ken Nakata|Cell culturing method by biomechanical stimulus load and its device|

---

CA2574128C|2004-07-27|2012-10-09|Dsm Ip Assets B.V.|Process for making a carbon nanotubes / ultra-high molar mass polyethylene composite fibre|

---

US20060134772A1|2004-11-18|2006-06-22|The Regents Of The University Of California|System for locating cells and for cellular analysis|

---

WO2006095330A2|2005-03-10|2006-09-14|Yeda Research And Development Co. Ltd.|Methods and immunogenic cell preparations for treating antigen-associated diseases|

---

US7704743B2|2005-03-30|2010-04-27|Georgia Tech Research Corporation|Electrosonic cell manipulation device and method of use thereof|

---

US7993821B2|2005-08-11|2011-08-09|University Of Washington|Methods and apparatus for the isolation and enrichment of circulating tumor cells|

---

WO2007067032A1|2005-12-09|2007-06-14|Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam|Means and methods for influencing the stability of cells|

---

WO2007097934A2|2006-02-17|2007-08-30|Elusys Therapeutics, Inc.|Methods and compositions for using erythrocytes as carriers for delivery of drugs|

---

US8293524B2|2006-03-31|2012-10-23|Fluxion Biosciences Inc.|Methods and apparatus for the manipulation of particle suspensions and testing thereof|

---

US20070249038A1|2006-04-21|2007-10-25|Andrea Adamo|Microfluidic device for single cell targeted operations|

---

AU2007284454A1|2006-08-17|2008-02-21|Massachusetts Institute Of Technology|Method and apparatus for microfluidic injection|

---

US20080311140A1|2007-05-29|2008-12-18|Baylor College Of Medicine|Antigen specific immunosuppression by dendritic cell therapy|

---

US8841135B2|2007-06-20|2014-09-23|University Of Washington|Biochip for high-throughput screening of circulating tumor cells|

---

AU2008264598B2|2007-06-21|2014-06-19|National University Corporation Nagoya University|Method for introducing foreign substance into cell having cell wall|

---

FR2919804B1|2007-08-08|2010-08-27|Erytech Pharma|COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE|

---

GB0718160D0|2007-09-18|2007-10-24|Medical Res Council|Methods|

---

EP2057998A1|2007-10-31|2009-05-13|Universitätsklinikum Hamburg-Eppendorf|Use of modified cells for the treatment of multiple sclerosis|

---

CN101874201B|2007-11-28|2012-08-15|柯尼卡美能达精密光学株式会社|Blood fluidity measurement apparatus and blood fluidity measurement method|

---

US20090280518A1|2008-05-12|2009-11-12|Massachusetts Institute Of Technology|System for high throughput measurement of mechanical properties of cells|

---

JP2010002582A|2008-06-19|2010-01-07|Konica Minolta Business Technologies Inc|Image forming apparatus|

---

WO2010010513A2|2008-07-21|2010-01-28|Trium Investments Limited|Solar panel mounting arrangement|

---

JP5137129B2|2008-07-23|2013-02-06|国立大学法人山口大学|Measuring device for mechanical properties of blood cells|

---

US9115340B2|2008-08-08|2015-08-25|Agency For Science Technology & Research|Microfluidic continuous flow device|

---

US8211656B2|2008-08-13|2012-07-03|The Invention Science Fund I, Llc|Biological targeting compositions and methods of using the same|

---

US20110091973A1|2008-12-09|2011-04-21|Glaser Larry F|Modified and fusion enhanced erythrocytes, cells and uses thereof|

---

US9157550B2|2009-01-05|2015-10-13|The Board Of Trustees Of The University Of Illinois|Microfluidic systems and methods|

---

EP2405959A4|2009-03-13|2013-10-16|Univ Tufts|Methods, apparatuses, and kits for introducing genetic material into living cells|

---

US9017991B2|2009-03-13|2015-04-28|Tufts University|Methods tip assemblies and kits for introducing material into cells|

---

US20120107925A1|2009-03-20|2012-05-03|Mo Huang Li|Devices for separating cells and methods of using them|

---

WO2010129671A2|2009-05-08|2010-11-11|Chauncey Sayre|Method of and apparatus for changing one type of cell into another type of cell|

---

GB0909754D0|2009-06-05|2009-07-22|Magnani Mauro|Drug delivery systems|

---

US20110300205A1|2009-07-06|2011-12-08|Novartis Ag|Self replicating rna molecules and uses thereof|

---

US9364831B2|2009-08-08|2016-06-14|The Regents Of The University Of California|Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting|

---

HUE029150T2|2009-10-27|2017-02-28|Erytech Pharma|Composition to induce specific immune tolerance|

---

CA2951341A1|2009-12-21|2011-06-30|Keygene N.V.|Improved techniques for transfecting protoplasts|

---

US9005579B2|2010-01-05|2015-04-14|Contrafect Corporation|Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria|

---

US8844570B2|2010-02-01|2014-09-30|California Institute Of Technology|Generating binary states using a microfluidic channel|

---

JP5704590B2|2010-02-05|2015-04-22|国立大学法人東京農工大学|Detection of circulating tumor cells using size-selective microcavity array|

---

US20110293558A1|2010-03-22|2011-12-01|Massachusetts Institute Of Technology|Material properties of t cells and related methods and compositions|

---

EP2665540A1|2011-01-19|2013-11-27|The University of British Columbia|Apparatus and method for particle separation|

---

EP2681306B1|2011-02-28|2019-01-09|President and Fellows of Harvard College|Cell culture system|

---

US9902990B2|2011-05-27|2018-02-27|The University Of British Columbia|Microfluidic cell trap and assay apparatus for high-throughput analysis|

---

MX2013013243A|2011-07-05|2014-05-30|Sotio As|Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells.|

---

US20130065314A1|2011-08-25|2013-03-14|Phytocentric Biotech Inc.|Algal transformation systems, compositions and methods|

---

RS59898B1|2011-10-17|2020-03-31|Massachusetts Inst Technology|Intracellular delivery|

---

EP2858630A4|2012-06-07|2016-02-24|Harvard College|Nanotherapeutics for drug targeting|

---

US9255245B2|2012-07-03|2016-02-09|Agilent Technologies, Inc.|Sample probes and methods for sampling intracellular material|

---

CN102925337B|2012-11-08|2014-06-18|武汉友芝友生物制药有限公司|Microfluid cell capturing chip and manufacture method thereof|

---

US8697359B1|2012-12-12|2014-04-15|The Broad Institute, Inc.|CRISPR-Cas systems and methods for altering expression of gene products|

---

GB201300052D0|2013-01-03|2013-02-20|Transimmune Ag|Method for obtaining immuno-suppressive dendritic cells|

---

GB201300049D0|2013-01-03|2013-02-20|Transimmune Ag|Method for obtaining immuno-stimulatory dendritic cells|

---

WO2014120956A1|2013-01-30|2014-08-07|Asta Fluidic Technologies, Inc.|Microfluidic-based fetal red blood cell detection|

---

US9725709B2|2013-03-12|2017-08-08|OpenCell Technologies, Inc.|Intracellular delivery and transfection methods and devices|

---

CN105452471A|2013-03-15|2016-03-30|加利福尼亚大学董事会|High-throughput cargo delivery into live cells using photothermal platforms|

---

KR20140115560A|2013-03-21|2014-10-01|인하대학교 산학협력단|Method of modifying characteristics of cells by mechanical stress and device for the same|

---

AU2014248119B2|2013-04-03|2019-06-20|Memorial Sloan-Kettering Cancer Center|Effective generation of tumor-targeted T-cells derived from pluripotent stem cells|

---

PL3033184T3|2013-08-16|2021-09-20|Massachusetts Institute Of Technology|Selective delivery of material to cells|

---

EP3060648A4|2013-10-22|2017-05-31|Cellanyx Diagnostics, LLC|Systems, devices and methods for microfluidic culturing, manipulation and analysis of tissues and cells|

---

JP6735233B2|2014-04-01|2020-08-05|ルビウス セラピューティクス， インコーポレイテッド|Immunoregulatory methods and compositions|

---

WO2015103331A1|2013-12-31|2015-07-09|Canon U.S. Life Sciences, Inc.|Methods and systems for continuous flow cell lysis in a microfluidic device|

---

SG11201608701QA|2014-04-18|2016-11-29|Editas Medicine Inc|Crispr-cas-related methods, compositions and components for cancer immunotherapy|

---

WO2016003485A1|2014-07-03|2016-01-07|Massachusetts Institute Of Technology|Microfluidic assay for rapid optimization of cell electroporation|

---

CN107109362A|2014-10-31|2017-08-29|麻省理工学院|Biomolecule is delivered to immunocyte|

---

JP6846345B2|2014-11-14|2021-03-24|マサチューセッツ インスティテュート オブ テクノロジー|Destruction and field delivery of compounds and compositions to cells|

---

US9744533B2|2014-12-10|2017-08-29|Berkeley Lights, Inc.|Movement and selection of micro-objects in a microfluidic apparatus|

---

CA2973117C|2015-01-07|2019-04-16|Indee. Inc.|A method for mechanical and hydrodynamic microfluidic transfection and apparatus therefor|

---

CA2971626A1|2015-01-12|2016-07-21|Massachusetts Institute Of Technology|Gene editing through microfluidic delivery|

---

US20180135012A1|2015-05-13|2018-05-17|Rubius Therapeutics, Inc.|Membrane-receiver complex therapeutics|

---

GB201513278D0|2015-07-03|2015-09-09|Transimmune Ag And Yale University|Device and method for obtaining immunostimulatory antigen-presenting cells|

---

CA2988996A1|2015-07-09|2017-01-12|Massachusetts Institute Of Technology|Delivery of materials to anucleate cells|

---

US20180245089A1|2015-09-04|2018-08-30|Sqz Biotechnologies Company|Intracellular delivery of biomolecules to cells comprising a cell wall|

---

EP3344747A1|2015-09-04|2018-07-11|SQZ Biotechnologies Company|Intracellular delivery of biomolecules mediated by a surface with pores|

---

CN108883133A|2015-12-22|2018-11-23|善威生物私人有限公司|Use the treatment method of red blood cell|

---

DK3402491T3|2016-01-11|2022-02-14|Rubius Therapeutics Inc|COMPOSITIONS AND PROCEDURES REGARDING MULTIMODAL THERAPY CELL SYSTEMS FOR CANCER INDICATIONS|

---

EP3402890A1|2016-01-12|2018-11-21|SQZ Biotechnologies Company|Intracellular delivery of complexes|

---

CN109475577A|2016-05-03|2019-03-15|Sqz生物技术公司|Intracellular delivery biomolecule is with inducing tolerance|

---

US20190111082A1|2016-05-03|2019-04-18|Sqz Biotechnologies Company|Intracellular delivery of biomolecules to induce tolerance|

---

US20170326213A1|2016-05-16|2017-11-16|Augusta University Research Institute, Inc.|Protein-Coupled Red Blood Cell Compositions and Methods of Their Use|

---

CN106244543A|2016-07-29|2016-12-21|北京时合生物科技有限公司|A kind of method that PBMC Differentiation Induction in vitro becomes dendritic cell|

---

US11198127B2|2016-11-08|2021-12-14|Georgia Tech Research Corporation|Methods for convectively-driven intracellular delivery|RS59898B1|2011-10-17|2020-03-31|Massachusetts Inst Technology|Intracellular delivery|

---

US11046596B2|2012-10-25|2021-06-29|Hydrus Technology Pty. Ltd.|Electrochemical liquid treatment apparatus|

---

US9725709B2|2013-03-12|2017-08-08|OpenCell Technologies, Inc.|Intracellular delivery and transfection methods and devices|

---

GB201308946D0|2013-05-16|2013-07-03|The Technology Partnership Plc|Method and device|

---

ITPD20130220A1|2013-08-02|2015-02-03|Univ Padova|METHOD FOR REPROGRAMMING AND CELLULAR PROGRAMMING BY USING MICROFLUID TECHNOLOGY|

---

PL3033184T3|2013-08-16|2021-09-20|Massachusetts Institute Of Technology|Selective delivery of material to cells|

---

JP6735233B2|2014-04-01|2020-08-05|ルビウス セラピューティクス， インコーポレイテッド|Immunoregulatory methods and compositions|

---

AU2014348683B2|2013-11-18|2020-11-05|Rubius Therapeutics, Inc.|Synthetic membrane-receiver complexes|

---

US11046595B2|2014-05-23|2021-06-29|Hydrus Technology Pty. Ltd.|Electrochemical treatment methods|

---

CN106660836B|2014-05-23|2020-12-15|海卓斯科技有限公司|Electrochemical treatment method|

---

WO2016003485A1|2014-07-03|2016-01-07|Massachusetts Institute Of Technology|Microfluidic assay for rapid optimization of cell electroporation|

---

US10081816B1|2014-07-03|2018-09-25|Nant Holdings Ip, Llc|Mechanical transfection devices and methods|

---

US10760040B1|2014-07-03|2020-09-01|NanoCav, LLC|Mechanical transfection devices and methods|

---

CN107109362A|2014-10-31|2017-08-29|麻省理工学院|Biomolecule is delivered to immunocyte|

---

JP6846345B2|2014-11-14|2021-03-24|マサチューセッツ インスティテュート オブ テクノロジー|Destruction and field delivery of compounds and compositions to cells|

---

EP3037518B1|2014-12-28|2020-05-06|Femtobiomed Inc.|Device for putting material into cell|

---

KR20160079661A|2014-12-28|2016-07-06|주식회사 펨토펩|Modified Cell by Putting Material into the Cell without Using Vehicle|

---

EP3037515A1|2014-12-28|2016-06-29|Femtofab Co., Ltd.|Modified cell prepared by putting material into the cell without using delivery vehicle|

---

EP3037517A1|2014-12-28|2016-06-29|Femtofab Co., Ltd.|Process for modifying a cell by putting material into the cell|

---

CA2973117C|2015-01-07|2019-04-16|Indee. Inc.|A method for mechanical and hydrodynamic microfluidic transfection and apparatus therefor|

---

CA2971626A1|2015-01-12|2016-07-21|Massachusetts Institute Of Technology|Gene editing through microfluidic delivery|

---

JP6886404B2|2015-01-30|2021-06-16|ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ|Protein delivery in primary hematopoietic cells|

---

WO2016168680A1|2015-04-17|2016-10-20|Exocyte Therapeutics Pte Ltd.|Method for developing exosome-based vaccines|

---

CA2988996A1|2015-07-09|2017-01-12|Massachusetts Institute Of Technology|Delivery of materials to anucleate cells|

---

PL3325081T3|2015-07-24|2021-12-20|Sorrento Therapeutics, Inc.|Methods for lymphatic delivery of active agents|

---

CA2991455A1|2015-07-24|2017-02-02|Kimberly-Clark Worldwide, Inc.|Methods for better delivery of active agents to tumors|

---

CN105384825B|2015-08-11|2018-06-01|南京传奇生物科技有限公司|A kind of bispecific chimeric antigen receptor and its application based on single domain antibody|

---

JP2018526992A|2015-08-31|2018-09-20|アイ ピース，インコーポレイテッド|Pluripotent stem cell production system, stem cell induction method, stem cell suspension culture method, stem cell suspension incubator, method for producing induced pluripotent stem cells, and method for producing specific somatic cells from animal cells|

---

EP3344747A1|2015-09-04|2018-07-11|SQZ Biotechnologies Company|Intracellular delivery of biomolecules mediated by a surface with pores|

---

US20180245089A1|2015-09-04|2018-08-30|Sqz Biotechnologies Company|Intracellular delivery of biomolecules to cells comprising a cell wall|

---

US20180327706A1|2015-10-19|2018-11-15|The Methodist Hospital|Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation|

---

BR112018013065A2|2015-12-28|2018-12-11|Intellia Therapeutics Inc|compositions and methods for the treatment of hemoglobinopathies|

---

EP3402890A1|2016-01-12|2018-11-21|SQZ Biotechnologies Company|Intracellular delivery of complexes|

---

US20190275520A1|2016-03-31|2019-09-12|Massachusetts Institute Of Technology|Flow-through microfluidic methods and devices featuring membrane-perturbing surface interactions for intracellular delivery|

---

US11225638B2|2016-04-04|2022-01-18|CyteQuest, Inc.|System, device and method for electroporation of cells|

---

WO2017179064A1|2016-04-11|2017-10-19|Indian Institute Of Technology, Bombay|Microdevice for separating plasma from human blood|

---

US20190111082A1|2016-05-03|2019-04-18|Sqz Biotechnologies Company|Intracellular delivery of biomolecules to induce tolerance|

---

CN109475577A|2016-05-03|2019-03-15|Sqz生物技术公司|Intracellular delivery biomolecule is with inducing tolerance|

---

WO2017201378A1|2016-05-19|2017-11-23|University Of Rochester|Micro-slits for reticulocyte maturation|

---

US20190136224A1|2016-05-31|2019-05-09|Massachusetts Institute Of Technology|Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform|

---

EP3463664A1|2016-06-06|2019-04-10|The Charles Stark Draper Laboratory, Inc.|Systems and methods for cell transduction|

---

WO2018039084A1|2016-08-20|2018-03-01|The Regents Of The University Of California|High-throughput system and method for the temporary permeablization of cells|

---

WO2018047149A1|2016-09-12|2018-03-15|Texas Children's Hospital|Cell filtration as a means of introducing exogenous material into a cell|

---

SG11201903189PA|2016-10-21|2019-05-30|Agency Science Tech & Res|Device, system and method for intracellular delivery of substances|

---

US11198127B2|2016-11-08|2021-12-14|Georgia Tech Research Corporation|Methods for convectively-driven intracellular delivery|

---

US10011848B2|2016-11-09|2018-07-03|City University Of Hong Kong|System and method for delivery of substance into mammalian cells|

---

CN106525273B|2016-11-24|2018-10-30|哈尔滨工业大学|cell temperature sensor based on quantum dot film and preparation method thereof|

---

TW201839136A|2017-02-06|2018-11-01|瑞士商諾華公司|Compositions and methods for the treatment of hemoglobinopathies|

---

CA3083118A1|2017-11-22|2019-05-31|Iovance Biotherapeutics, Inc.|Expansion of peripheral blood lymphocytesfrom peripheral blood|

---

EP3638798A4|2017-06-16|2021-03-03|Neem Scientific, Inc.|Nanoneedle and related apparatus and methods|

---

CR20200251A|2017-11-17|2020-07-17|Iovance Biotherapeutics Inc|Til expansion from fine needle aspirates and small biopsies|

---

EP3720878A1|2017-12-05|2020-10-14|SQZ Biotechnologies Company|Intracellular delivery of biomolecules to modulate antibody production|

---

CA3086210A1|2017-12-20|2019-06-27|Sqz Biotechnologies Company|System for delivery of a payload into a cell|

---

EP3737743A1|2018-01-08|2020-11-18|Iovance Biotherapeutics, Inc.|Processes for generating til products enriched for tumor antigen-specific t-cells|

---

WO2019136459A1|2018-01-08|2019-07-11|Iovance Biotherapeutics, Inc.|Processes for generating til products enriched for tumor antigen-specific t-cells|

---

EP3765068A2|2018-03-12|2021-01-20|SQZ Biotechnologies Company|Intracellular delivery of biomolecules to modify immune response|

---

CR20200461A|2018-03-12|2021-03-11|Sqz Biotechnologies Co|Methods for treating hpv-associated diseases|

---

KR20200133219A|2018-03-15|2020-11-26|케이에스큐 세러퓨틱스 인코포레이티드|Gene-modulating compositions and methods for improved immunotherapy|

---

EP3556845A1|2018-04-20|2019-10-23|Cellix Limited|A method and device for transfecting cells|

---

WO2020005802A1|2018-06-24|2020-01-02|University Of Oregon|Microinjection chip, device, system and uses thereof for unicellular or multicellular organisms|

---

CA3115245A1|2018-10-04|2020-04-09|Sqz Biotechnologies Company|Intracellular delivery of biomolecules to enhance antigen presenting cell function|

---

PE20211292A1|2018-11-05|2021-07-20|Iovance Biotherapeutics Inc|PROCESSES FOR THE PRODUCTION OF INFILTRATING TUMOR LYMPHOCYTES AND USES OF THESE IN IMMUNOTHERAPY|

---

CA3118616A1|2018-11-05|2020-05-14|Iovance Biotherapeutics, Inc.|Selection of improved tumor reactive t-cells|

---

KR20210091212A|2018-11-05|2021-07-21|이오반스 바이오테라퓨틱스, 인크.|Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies|

---

JP2022506508A|2018-11-05|2022-01-17|アイオバンス バイオセラピューティクス，インコーポレイテッド|Expanded culture of TIL using AKT pathway inhibitors|

---

KR102232757B1|2018-11-22|2021-03-26|엑솔런스바이오테크놀로지|Delivery device of target material using extracorporeal shock wave|

---

KR20210148075A|2018-12-04|2021-12-07|셀에프이, 인크.|Methods and systems for intracellular delivery|

---

CA3123392A1|2018-12-19|2020-06-25|Iovance Biotherapeutics, Inc.|Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof|

---

WO2020154696A1|2019-01-25|2020-07-30|Sqz Biotechnologies Company|Anucleate cell-derived vaccines|

---

BR112021016875A2|2019-03-01|2022-01-04|Iovance Biotherapeutics Inc|Process for expansion of peripheral blood lymphocytes|

---

KR102217407B1|2019-03-12|2021-02-22|고려대학교 산학협력단|Inertia based microfluidic intracellular delivery platforms and intracellular mass transfer method using the same|

---

WO2020184992A1|2019-03-12|2020-09-17|고려대학교 산학협력단|Microfluidic system for intracellular delivery of substances and method therefor|

---

EP3938401A1|2019-03-15|2022-01-19|Cartesian Therapeutics, Inc.|Anti-bcma chimeric antigen receptors|

---

EP3953039A1|2019-04-08|2022-02-16|SQZ Biotechnologies Company|Cartridge for use in a system for delivery of a payload into a cell|

---

WO2020207456A1|2019-04-11|2020-10-15|The Chinese University Of Hong Kong|Systems and methods for controlled membrane disruption|

---

WO2020232029A1|2019-05-13|2020-11-19|Iovance Biotherapeutics, Inc.|Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy|

---

WO2020232418A1|2019-05-15|2020-11-19|Cellfe, Inc.|Intracellular delivery|

---

WO2020252215A1|2019-06-12|2020-12-17|Cellfe, Inc.|Methods and systems for cell labeling and imaging|

---

SG11202112092TA|2019-06-25|2021-11-29|Inari Agriculture Technology Inc|Improved homology dependent repair genome editing|

---

CN110272810A|2019-07-01|2019-09-24|广州世赛生物科技有限公司|Allogenic material is delivered to device and method and its application in eukaryocyte|

---

KR20210054698A|2019-11-06|2021-05-14|고려대학교 산학협력단|A method and platform for intracellular delivery using droplet microfluidics|

---

WO2021091205A1|2019-11-06|2021-05-14|고려대학교 산학협력단|Droplet deformation-based method of transferring material into cells and chip for same|

---

WO2021118990A1|2019-12-11|2021-06-17|Iovance Biotherapeutics, Inc.|Processes for the production of tumor infiltrating lymphocytesand methods of using the same|

---

WO2021123920A1|2019-12-18|2021-06-24|Novartis Ag|Compositions and methods for the treatment of hemoglobinopathies|

---

WO2021226061A1|2020-05-04|2021-11-11|Iovance Biotherapeutics, Inc.|Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy|

---

WO2021226085A1|2020-05-04|2021-11-11|Iovance Biotherapeutics, Inc.|Selection of improved tumor reactive t-cells|

---

WO2021231278A1|2020-05-11|2021-11-18|F. Hoffmann-La Roche Ag|Combination therapy with modified pbmcs and an immunoconjugate|

---

WO2021237164A1|2020-05-22|2021-11-25|Sqz Biotechnologies Company|Point of care system for automatically processing cells|

---

WO2022026620A1|2020-07-29|2022-02-03|Sqz Biotechnologies Company|Methods to stimulate immune responses to mutant ras using nucleated cells|

---

WO2022026621A1|2020-07-29|2022-02-03|Sqz Biotechnologies Company|Methods to stimulate immune responses to mutant ras using anucleate cells|

---

CN112268934A|2020-09-16|2021-01-26|东南大学|Detection chip and detection method for circulating tumor cells|

法律状态:
2018-03-27| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-06-04| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|

---

2019-12-10| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2020-04-07| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-09-15| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161548013P| true| 2011-10-17|2011-10-17|

---

US61/548,013|2011-10-17|

---

US201261684301P| true| 2012-08-17|2012-08-17|

---

US61/684,301|2012-08-17|

---

PCT/US2012/060646|WO2013059343A1|2011-10-17|2012-10-17|Intracellular delivery|

---